

1 **Title: *ATRAID* regulates the action of nitrogen-containing bisphosphonates on bone**

2
3 **Authors:** Lauren E. Surface^{1,&}, Damon T. Burrow², Jinmei Li², Jiwoong Park², Sandeep Kumar²,
4 Cheng Lyu², Niki Song², Zhou Yu^{1,^}, Abhirami Rajagopal^{3,#}, Yangjin Bae³, Brendan H. Lee³,
5 Steven Mumm^{2,4}, Charles C. Gu⁵, Jonathan C. Baker⁶, Mahshid Mohseni², Melissa Sum⁷,
6 Margaret Huskey², Shenghui Duan², Vinieth N. Bijanki⁴, Roberto Civitelli², Michael J. Gardner⁸,
7 Chris M. McAndrew⁹, William M. Ricci¹⁰, Christina A. Gurnett^{9,11}, Kathryn Diemer², Fei Wan¹²,
8 Christina L. Costantino¹³, Kristen M. Shannon¹⁴, Noopur Raje¹⁴, Thomas B. Dodson^{15,@}, Daniel
9 A. Haber^{14,16}, Jan E. Carette¹⁷, Malini Varadarajan¹⁸, Thijn R. Brummelkamp¹⁹⁻²¹, Kivanc
10 Birsoy²², David M. Sabatini^{16,23-25}, Gabe Haller^{11,26}, Timothy R. Peterson^{2,27,28*}

11
12 **Affiliations:**

13 ¹ Department of Molecular and Cellular Biology, Department of Chemistry and Chemical
14 Biology, Faculty of Arts and Sciences Center for Systems Biology, Harvard University,
15 Cambridge, MA 02138, USA.

16 [&] (present address) Endocrine Unit, 55 Fruit St., Massachusetts General Hospital, Harvard
17 Medical School, Boston, MA, 02114, USA.

18 [^] (present address) Howard Hughes Medical Institute (HHMI) Janelia Research Campus, 19700
19 Helix Drive, Ashburn, Virginia 20147, USA.

20 ² Division of Bone & Mineral Diseases, Department of Medicine, Washington University School
21 of Medicine, BJC Institute of Health, 425 S. Euclid Ave., St. Louis, MO 63110, USA.

22 ³ Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX,
23 77030, USA.

24 [#] (present address) Harris County Public health, Houston, TX, 77027, USA.

25 ⁴ Center for Metabolic Bone Disease and Molecular Research, Shriners Hospital for Children,
26 St. Louis, MO 63110, USA.

27 ⁵ Division of Biostatistics, Washington University School of Medicine, 660 S. Euclid Ave.,
28 Campus Box 8067, St. Louis, MO 63110, USA.

29 ⁶ Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S.
30 Kingshighway Blvd. Louis, MO 63110, USA.

31 ⁷ Division of Endocrinology, Diabetes and Metabolism, NYU Langone Health, 530 1st Ave.,
32 Schwartz 5E. New York, NY 10016, USA.

33 ⁸ Stanford University, Department of Orthopedic Surgery, 450 Broadway Street, Redwood City,
34 CA 94063, USA.

35 ⁹ Department of Orthopedic Surgery, Washington University School of Medicine, 4938 Parkview
36 Place, St. Louis, MO 63110, USA.

37 ¹⁰ Hospital for Special Surgery Main Campus - Belaire Building, 525 East 71st Street 2nd Floor,
38 New York, NY 10021, USA.

39 ¹¹ Department of Neurology, Washington University School of Medicine, Campus Box 8111, 660
40 S. Euclid Ave., St. Louis, MO 63110, USA.

41 ¹² Department of Surgery, Washington University School of Medicine, Campus Box 8109, 4590
42 Children's Place, Suite 9600, St. Louis, MO 63110, USA.

43 ¹³ Massachusetts General Hospital Cancer Center and Department of Surgery, Harvard Medical
44 School, Boston, MA 02114, USA.

45 ¹⁴ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114,
46 USA.

47 ¹⁵ Department of Oral and Maxillofacial Surgery, Massachusetts General Hospital and Harvard
48 School of Dental Medicine, Boston, MA 02114, USA.

49 @ (present address) Department of Oral and Maxillofacial Surgery, University of Washington
50 School of Dentistry, Seattle, WA 98195, USA.

51 ¹⁶ Howard Hughes Medical Institute (HHMI), Chevy Chase, MD 20815, USA.

52 ¹⁷ Department of Microbiology and Immunology, Stanford University School of Medicine,
53 Stanford, CA 94305, USA.

54 ¹⁸ Oncology Disease Area, Novartis institutes for biomedical research, Cambridge, CA 02140,
55 USA.

56 ¹⁹ Oncode Institute, Division of Biochemistry, the Netherlands Cancer Institute, Plesmanlaan 121,
57 1066CX, Amsterdam, Netherlands.

58 ²⁰ CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090
59 Vienna, Austria.

60 ²¹ Cancer Genomics Center, Plesmanlaan 121, 1066CX, Amsterdam, Netherlands.

61 ²² The Rockefeller University, 1230 York Ave, New York 10065, USA.

62 ²³ Whitehead Institute, 9 Cambridge Center, Cambridge, MA 02139, USA.

63 ²⁴ Department of Biology, Massachusetts Institute of Technology (MIT), 77 Massachusetts
64 Avenue, Cambridge, MA 02139, USA.

65 ²⁵ David H. Koch Center for Integrative Cancer Research at MIT, 77 Massachusetts Avenue,
66 Cambridge, MA 02139, USA.

67 ²⁶ Department of Neurosurgery, Washington University School of Medicine, Campus Box 8057,
68 660 S. Euclid Ave., St. Louis, MO 63110, USA.

69 ²⁷ Department of Genetics, Washington University School of Medicine, 4515 McKinley Ave.
70 Campus Box 8232, St. Louis, MO 63110, USA.

71 ²⁸ Institute for Public Health, Washington University School of Medicine, 600 S. Taylor Suite
72 2400, Campus Box 8217, St. Louis, MO 63110, USA.

73 Corresponding author: * timpeterson@wustl.edu (T.R.P).

74

75 **One Sentence Summary:** *ATRAID* is essential for responses to the commonly prescribed
76 osteoporosis drugs nitrogen-containing bisphosphonates.

77

78 **Overline: BONE**

79

80 **Abstract:**

81

82 Nitrogen-containing bisphosphonates (N-BPs), such as alendronate, are the most widely
83 prescribed medications for diseases involving bone, with nearly 200 million prescriptions written
84 annually. Recently, widespread use of N-BPs has been challenged due to the risk of rare but
85 traumatic side effects such as atypical femoral fracture (AFFs) and osteonecrosis of the jaw
86 (ONJ). N-BPs bind to and inhibit farnesyl diphosphate synthase (FDPS), resulting in defects in
87 protein prenylation. Yet it remains poorly understood what other cellular factors might allow N-
88 BPs to exert their pharmacological effects. Here, we performed genome-wide studies in cells
89 and patients to identify the poorly characterized gene, *ATRAID*. Loss of *ATRAID* function results

90 in selective resistance to N-BP-mediated loss of cell viability and the prevention of alendronate-
91 mediated inhibition of prenylation. *ATRAID* is required for alendronate inhibition of osteoclast
92 function, and *ATRAID*-deficient mice have impaired therapeutic responses to alendronate in
93 both postmenopausal and senile (old age) osteoporosis models. Lastly, we performed exome
94 sequencing on patients taking N-BPs that suffered ONJ or an AFF. *ATRAID* is one of three
95 genes that contain rare non-synonymous coding variants in patients with ONJ or AFF that is
96 also differentially expressed in poor outcome groups of patients treated with N-BPs. We
97 functionally validated this patient variation in *ATRAID* as conferring cellular hypersensitivity to N-
98 BPs. Our work adds key insight into the mechanistic action of N-BPs and the processes that
99 might underlie differential responsiveness to N-BPs in people.

100

101

102 INTRODUCTION

103 Nitrogen-containing bisphosphonates (N-BPs) are the standard treatment for osteoporosis and
104 several other bone diseases (1, 2). Certain N-BPs (pamidronate, zoledronate) are also routinely
105 prescribed to prevent skeletal complications in patients with multiple myeloma and with bone
106 metastases from other malignancies, including breast and prostate cancer (3). However,
107 because N-BPs cause rare yet serious side-effects, such as atypical fractures (AFFs) and
108 osteonecrosis of the jaw (ONJ), many patients avoid taking them (1, 4-6), causing the number of
109 prescriptions to plummet over 50% in the last decade (6, 7). A plan for addressing this crisis,
110 developed by American Society for Bone and Mineral Research (ASBMR) leadership, calls for
111 better pharmacogenomics to identify genetic factors that may underlie response to this class of
112 drugs (6).

113

114 A goal of personalized medicine is to identify biomarkers that underlie drug responsiveness. For
115 N-BPs, it can be said that there are limited personalization options owing to the limited number
116 of genes implicated in the pharmacologic effects of N-BPs. Exposure of cells to N-BPs leads to
117 inhibition of farnesyl diphosphate synthase (FDPS, also known as FPPS) resulting in reduction
118 in protein prenylation (8). On the basis of this observation, it is widely believed that N-BPs act
119 therapeutically by impairing protein prenylation, ultimately leading to deficits in numerous
120 cellular processes including differentiation, recruitment, and adhesion of osteoclasts (the major
121 bone resorptive cell type) to bone and/or osteoclast cell death (9-11).

122

123 Recently we performed CRISPRi-based, genome-wide screening and identified a poorly
124 characterized gene, *SLC37A3*, that provides molecular details for how N-BPs reach their target,
125 FDPS (12). As part of that work we determined that *SLC37A3* requires another poorly
126 characterized protein, *ATRAID*, for its expression (12). Here, we independently identified
127 *ATRAID* using a different genome-wide, mutagenesis strategy. We generated *Atraid*-deficient

128 mice and determined that it is required for the regulation of N-BPs on bone. We also performed
129 exome sequencing in patients taking N-BPs and identified and functionally validated rare coding
130 variants in *ATRAID* in patients that suffered side effects, namely atypical femoral fractures and
131 osteonecrosis of the jaw.

132

133 RESULTS

134 ***ATRAID* is required for molecular responses to nitrogen-containing bisphosphonates**

135 To provide insight into the mechanism(s) of N-BPs action, we performed a genetic screen to
136 identify human genes required for the anti-proliferative effects of N-BPs (Fig. 1A). We used a
137 largely haploid human cell line of myeloid origin (KBM7, also known as HAP1) to generate a
138 library of retroviral gene trap mutants (13) and then selected for clones that are resistant to
139 cytotoxic concentrations of alendronate (ALN). The advantages of this cell line for genetic
140 screening include: i) each gene is present as a single copy, enabling gene inactivation (except
141 those genes on chromosome 8); ii) KBM7 cells are human and of the hematopoietic lineage,
142 increasing the likelihood that any genes we identify could be relevant to the natural context for
143 N-BPs, the bones of human patients (14); and iii) it is a different cell line and a different
144 mutagenic approach than used previously with CRISPRi in K562 cells (12), which allows us to
145 independently assess those results. Using this haploid approach, we identified, *ATRAID*, also
146 known as *APR-3/C2orf28* (15), as the gene most significantly enriched for insertions in
147 alendronate-resistant cells compared to untreated cells (FDR corrected *P*-value = 7.02e-45)
148 (Fig. 1B; fig. S1, A and B, and table S1). Providing confidence in our screen, we also identified
149 *SLC37A3*, as well as *SNTG1*, *PLCL1*, and *EPHB1*, which have been previously connected to N-
150 BP action on bone cells and/or human bone diseases (table S1) (16-18).

151

152 *ATRAID* was named because it is a gene whose mRNA expression is strongly induced by the
153 ligand all-trans retinoic acid (15). *ATRAID* is conserved in chordates and contains a signal

154 peptide, Toll-like-receptor leucine rich repeat, EGF-like domain, and a transmembrane domain
155 (Fig. 1C and fig. S1A) (19, 20). The alendronate resistance phenotype of *ATRAID*-deficient cells
156 (*ATRAID_GT1* (gene-trap1) and *ATRAID_GT2* (gene-trap2)) was reversed by the re-introduction
157 of wild-type *ATRAID* splice variant 2 (v2) or splice variant 3 (v3) cDNA, which differ in their N-
158 termini (Fig. 1D; fig. S1, A and B). To better understand the degree of alendronate resistance in
159 *ATRAID*-deficient cells, we varied both cell number and drug concentration in the viability assay.
160 *ATRAID*-deficient cells were resistant to alendronate over two to three orders of magnitude of
161 drug concentration or cell number (fig. S1C). The growth of untreated wild-type and *ATRAID*-
162 deficient cells didn't differ (fig. S1D). Overexpression of full-length *ATRAID* (v2) sensitized cells
163 to alendronate (fig. S1E). Lastly, *ATRAID* membrane targeting is required for the anti-
164 proliferative effects of alendronate, as *ATRAID*-deficient cells complemented with full-length
165 *ATRAID* (v2) were sensitive to the cytotoxic effects of alendronate, whereas those expressing
166 the membrane truncated form remained resistant (fig. S1F). Taken together, these data
167 establish *ATRAID* as a genetic factor required for the growth inhibitory effects of alendronate.
168
169 N-BPs are part of a larger class of compounds known as bisphosphonates (BPs) that contain
170 two phosphate moieties each joined to a carbon atom by a carbon-phosphorus bond (21) (Fig.
171 1E). To determine whether the effects of *ATRAID* deficiency on alendronate resistance were
172 specific to nitrogen-containing bisphosphonates, we tested the effect of several nitrogen-
173 containing and non-nitrogen-containing bisphosphonates on wild-type and mutant *ATRAID* cells.
174 *ATRAID*-deficient cells were resistant to the nitrogen-containing bisphosphonates, alendronate
175 and zoledronate (ZOL), but were as sensitive to the non-nitrogen-containing bisphosphonates,
176 etidronate and tiludronate, as control cells (Fig. 1E).
177
178 To determine whether *ATRAID* is required for the reduction in protein prenylation observed
179 upon N-BP treatment, we monitored the prenylation of several proteins, including the heat shock

180 protein DnaJ (Hsp40) homolog HDJ-2, and the Ras family GTPase Rap1a (22). Alendronate
181 strongly inhibited prenylation of HDJ-2 and Rap1a in wild-type cells in a dose dependent
182 manner and had much less of an effect on prenylation of these proteins in *ATRAID*-deficient
183 cells (Fig. 1F). Furthermore, the inhibitory effect of alendronate on prenylation was rescued
184 when *ATRAID* cDNA variants (v2 and v3) were introduced (fig. S1F). We observed inhibition of
185 prenylation resistance at N-BP doses where we did not see PARP-1 cleavage in *ATRAID*
186 deficient cells, suggesting that *ATRAID* can mediate the effect on prenylation independent of
187 apoptosis (fig. S1G). Thus, these findings suggest *ATRAID* functions as a positive regulator
188 upstream of FDPS.

189

190 ***ATRAID* is required for organismal responses to nitrogen-containing bisphosphonates**

191 To determine whether *ATRAID* modulates organismal responses to N-BPs we inactivated *Atraid*
192 globally in mice (23). We confirmed deletion of *Atraid* exons 3-5 and determined that *Atraid*
193 homozygous deleted *Atraid*^{KO} mice (labeled KO, -/-) are viable but their body weight is mildly
194 reduced compared with litter-matched derived, wild-type controls (labeled as WT, +/+) (fig. S2,
195 A to C). We confirmed that tail fibroblasts derived from *Atraid*^{KO} animals are resistant to the
196 cytotoxic effects of alendronate (fig. S2, D and E). Before studying the effects of the N-BPs in
197 the context of *Atraid* loss, we first characterized the basal role of *Atraid* in bones. We
198 determined that *Atraid* mRNA expression was undetectable in the bones of *Atraid*^{KO} animals and
199 that *Atraid*^{KO} mice had slightly smaller bones compared with litter-matched derived, wild-type
200 control mice (fig. S2, F and G). To examine the effects of *Atraid* on bone structure, we
201 performed micro-computed tomography (μ CT) analysis (24). *Atraid* deficiency did not decrease
202 either trabecular or cortical structural parameters (fig. S2, H and I; data file S1). We measured
203 bone strength using three-point bending tests (25). Some measures, such as stiffness
204 (Newtons/millimeter, N/mm) and post-yield displacement (a measure of bone fragility, in
205 millimeters, mm) were decreased by *Atraid* deficiency, whereas others, such as yield load (the

206 point where bone bending goes from elastic vs. plastic, in Newtons, N), were not significantly
207 altered (fig. S2, J to L; data file S1, $P > 0.05$, student's t -test).
208
209 Osteoclasts release degradation products from C-terminal telopeptides of type I collagen (CTX-
210 I) from bone into blood (26), and CTX-I in serum was not significantly different in wild-type mice
211 compared with *Atraid*^{KO} mice (fig. S2M; data file S1, $P > 0.05$, student's t -test).
212 Histomorphometric measures of osteoclast function including osteoclast surface per bone
213 surface (Oc.S/BS) (27), as judged by Tartrate Resistant Acid Phosphatase (TRAP) staining
214 (28), were also not statistically different (fig. S2N; data file S2). Consistent with a basal defect in
215 osteoblast function (29), *Atraid*^{KO} mice have reduced serum circulating Gla-Osteocalcin [Gla-
216 OC; the activated form of osteocalcin, incorporated in bone matrix (30)] and modestly reduced
217 bone formation rate (BFR) as measured by double-labeling (27) (fig. S2, O and P; data file S1).
218
219 To test the effect of alendronate in a model that mimics menopausal bone loss, the most
220 common indication for the N-BPs, we performed ovariectomies (OVX) on adult female mice
221 (Fig. 2A) (31). When ovaries are removed from females, the changes in estrogen cause a
222 reduction in bone density triggered by disruption of the balance of osteoblast and osteoclast
223 functions. This loss of bone density can be alleviated by treatment with N-BPs (32). The
224 magnitude of trabecular bone loss in WT and *Atraid*^{KO} sham mice four weeks after OVX is
225 exemplified in the μ CT 3D reconstruction of the femoral proximal metaphysis (Fig. 2B).
226 Consistent with alendronate preventing bone loss (32), femoral cortical and trabecular structural
227 parameters, including cortical thickness and area, bone volume/trabecular volume (%), and
228 trabecular thickness, were increased by alendronate treatment of WT OVX mice (Fig. 2, C to F
229 and data file S1; see WT OVX +/- alendronate). In contrast, alendronate had blunted effects in
230 *Atraid*^{KO} OVX mice (Fig. 2, C to F and data file S1; see *ATRAID*^{KO} OVX +/- alendronate).

231

232 The same patterns of alendronate resistance in *Atraid*^{KO} mice were observed for bone strength
233 (Fig. 2, G and H). That is, alendronate increased bone strength as judged by stiffness and yield
234 load in wild-type ovariectomized mice, but its effects were blunted in *Atraid*^{KO} matched cohorts
235 (Fig. 2, G and H; data file S1). Taken together, these results suggest that *Atraid* is required for
236 the beneficial effects of N-BPs in ovariectomized female mice.

237

238 To test an additional osteoporosis model, we examined senile (old age) osteoporosis using 18
239 month-old male WT and *Atraid* deficient mice (33). After treating these mice weekly with
240 alendronate or saline for two months, we found similar results to those in our OVX study. That
241 is, measures of bone density were increased by alendronate, but less so in the *Atraid* deficient
242 mice (fig. S2, Q and R, data file S1). This further suggests *Atraid* is key for responses to N-BPs
243 in vivo.

244

245 ***ATRAID* is required cell-autonomously for N-BP inhibition of osteoclast function**

246 Because N-BPs potentially affect osteoclasts and osteoblasts, we investigated whether *Atraid*
247 deficiency would regulate the effects of alendronate in each cell type in our post-menopausal
248 (OVX) and old-age (senile) osteoporosis models. Regarding osteoclasts, in wild-type mice both
249 serum and bone histological markers of osteoclast function, CTX-I, and osteoclast surface per
250 bone surface (Oc.S/BS) and osteoclast number per bone surface (N.Oc/BS), respectively, were
251 impaired by alendronate treatment (Fig. 3, A and B; fig. S3, A and B; data file S2) in both
252 osteoporosis models. In contrast, in *Atraid*^{KO} mice, alendronate was less effective on
253 osteoclasts in both osteoporosis models (Fig. 3, A and B; fig. S3, A and B; data file S2). That
254 osteoclast number was reduced by N-BPs in wild-type mice is consistent with our cell viability
255 measurements in non-osteoclasts and with previous literature (32).

256

257 To provide insight into the effects of N-BPs on osteoblasts in our osteoporosis models, we
258 measured BFR and mineral apposition rate (MAR) (27). Unlike BFR in which the rate is
259 normalized by the amount of labeled bone surface, MAR is the rate of bone formation
260 irrespective of how much of the bone is active (27). Alendronate did not affect trabecular MAR
261 or BFR in either wild-type or *Atraid*^{KO} mice in either osteoporosis model (fig. S3, C and D; data
262 file S2).

263
264 To determine whether *Atraid* is required in a cell autonomous manner for the N-BP-dependent
265 effects on osteoclasts, we isolated M-CSF-expanded bone marrow macrophages (BMMs) from
266 both WT and *Atraid*^{KO} mice, and differentiated these cells into osteoclasts following a standard
267 protocol (34). *Atraid*^{KO} BMMs differentiated into osteoclasts as well as wild-type cells
268 irrespective of treatment with alendronate, yet BMM-derived *Atraid*^{KO} osteoclasts were resistant
269 to alendronate-induced apoptosis (Fig. 3, C and D). This suggests that *Atraid* is required cell
270 autonomously in osteoclasts for the effects of N-BPs on cell number.

271
272 As an independent confirmation of our primary cell experiments, we generated *Atraid* knockout
273 RAW 264.7 cells and differentiated them to osteoclasts (fig. S3E). RAW 264.7 cells are a
274 robust, well-characterized murine macrophage cell line that can be differentiated to osteoclast-
275 like cells using RANKL (35). We treated both RAW 264.7 cells and the RAW 264.7 cells
276 differentiated into osteoclasts with alendronate, and found *Atraid* deficiency, as expected,
277 conferred resistance to doses that induced apoptosis (Fig. 3E). Alendronate did not affect
278 known markers of osteoclast differentiation in wild-type cells (Fig. 3C). Therefore, to pursue the
279 mechanism of N-BPs on osteoclast function, we focused on prenylation. In alendronate-treated
280 RAW 264.7 cells and osteoclasts differentiated from RAW 264.7 cells, we found that *Atraid*^{KO}
281 cells were resistant to alendronate-induced inhibition of prenylation (Fig. 3F).

282

283 We assessed whether wild-type osteoblasts might sensitize *Atraid*-deficient osteoclasts to N-
284 BPs. We cultured primary wild-type osteoblasts with either WT or *Atraid*-deficient primary
285 osteoclasts and treated these co-cultures with alendronate or vehicle. As in the case of WT
286 RAW 264.7 cells grown independently (Fig. 3, E and F), WT osteoclasts were more inhibited by
287 alendronate than *Atraid* deficient osteoclasts despite the presence of WT osteoblasts in both
288 cases (Fig. 3, G and H). In total, these findings support that *Atraid* is required for the cell-
289 autonomous effects of N-BPs on osteoclasts.

290

291 **Genetic factors involved in responses to nitrogen-containing bisphosphonates in** 292 **patients**

293 We sought an unbiased approach to determine what genes might be relevant in patients treated
294 with N-BPs. We performed whole exome sequencing (WES) on two sets of patients taking N-
295 BPs who experienced side effects: patients with osteoporosis who experienced atypical femoral
296 fractures (AFF) (n = 27 patients), as well as patients with multiple myeloma or breast cancer
297 patients who experienced osteonecrosis of the jaw (ONJ) (n = 8 patients) and 11 control
298 patients taking N-BPs that didn't experience AFF or ONJ (Fig. 4A and data file S3 for patient
299 information). We also analyzed two published gene expression datasets involving patients who
300 had taken N-BPs: patients with multiple myeloma who did or did not suffer ONJ when taking N-
301 BPs (36), and patients with breast cancer with bone marrow disseminated tumor cells (DTC)
302 which reoccurred or the patient died less than 1000 days vs. greater than 2500 days following
303 initiation of zoledronate treatment (37) (Fig. 4A and data file S3). We then compared the patient
304 data to three cell-based, genome-wide CRISPRi and CRISPRa screens we previously
305 performed: alendronate and zoledronate CRISPRi and alendronate CRISPRa (12, 38) (data file
306 S3). To identify genes involved in N-BP response across experimental paradigms we generated
307 a Venn diagram to visualize the overlap of "hits". In comparing the WES hits –genes that had
308 the same rare coding variants (minor allele frequency < 0.05) in both patients with AFF and ONJ

309 but not in controls – with our hits from our alendronate and zoledronate CRISPRi/a screens, we
310 identified 64 genes in common including *ATRAID*, *FDPS*, and *SLC37A3* (Fig. 4A). When
311 comparing the WES hits with the gene expression hits, we identified 49 genes, whereas the
312 CRISPRi/a and gene expression studies had 76 genes in common (Fig. 4A). Three genes,
313 *ATRAID*, *ATR*, and *ZBTB4* were statistically significant in all three data types (Fig. 4A) (data file
314 S3, FDR corrected $P < 0.05$). Focusing on *ATRAID* specifically, we observed a ~50% decrease
315 in *ATRAID* expression in the patients with DTC and ONJ that had their gene expression
316 measured. By exome sequencing the patients with AFF and ONJ, in *ATRAID* we detected two
317 rare variants – hereafter referred to as the ‘D5G/G32R variant’ – that were present together in 3
318 out of 35 patients with AFF and ONJ (2 out of 27 AFF; 1 out of 8 ONJ) (Fig. 4B).

319
320 We sought to determine the functional relevance of decreased *ATRAID* mRNA expression and
321 the *ATRAID* D5G/G32R variant, both of which are associated with bad outcomes of N-BP
322 treatment (Fig. 4, A and B). To test the former, we expressed *ATRAID* mRNA at sub-
323 endogenous quantities in *ATRAID* deficient cells such that the expression was similar to the
324 reduced expression seen in patients that experienced ONJ or DTC (~50% compared to wild-
325 type controls) (Fig. 4C). We refer to these *ATRAID* partially restored cells as ‘*ATRAID*_{low expr.}’.
326 *ATRAID*-deficient cells conferred resistance to alendronate as expected, whereas *ATRAID*_{low expr.}
327 cells were hypersensitized to alendronate (Fig. 4D). Similarly, the *ATRAID* D5G/G32R variant,
328 which we identified in both the patients with AFF and ONJ, conferred hypersensitivity to
329 alendronate compared with wild-type *ATRAID* (Fig. 4, E and F). Taken together, this suggests
330 that bad patient outcomes might reflect cellular hyper-response to N-BPs. In total, these findings
331 support the importance of *ATRAID* in bisphosphonate responsiveness in humans.

332

333 **DISCUSSION**

334 This work focused on the physiological impact of *ATRAID* as a positive regulator genetically
335 upstream of *FDPS*. Here we use prenylation as an output of *FDPS* function. Recently, we linked
336 *FDPS* to DNA synthesis and damage (39). This was intriguing in light of earlier studies in the
337 context of ONJ where N-BPs regulated p63 – a well-known mediator of DNA damage (40) – in a
338 mevalonate pathway-dependent manner (41). Considering that each of the three top genes from
339 the patient analysis, *ATRAID*, *ATR*, and *ZBTB4*, are involved in p53 responses – a better known
340 p63-related mediator of DNA damage (42-45) – it will be interesting to determine whether these
341 genes mediate their effects on p53/p63 signaling via *FDPS*.

342
343 The molecular effects of N-BPs on *FDPS* require the transporter, *SLC37A3* (12). Interestingly,
344 the *SLC37A* family member (46), *SLC37A2*, is mutated in dogs and gives rise to a bone
345 overgrowth phenotype that resembles the human disease Caffey syndrome (47, 48). This
346 phenotype is particularly interesting because it suggests that natural ligands or drugs that inhibit
347 the *SLC37A* family might phenocopy N-BP treatment in increasing bone density.

348
349 *ATRAID* binds *NELL-1*, a secreted protein that promotes bone mineralization in mice and
350 potentiates osteoblast differentiation in an *ATRAID*-dependent manner (49, 50). It is also
351 notable that *NELL-1* is in pre-clinical testing for the treatment of osteoporosis (51). In future
352 studies, it will be interesting to determine whether *NELL-1* affects the responses to N-BPs we
353 observe upon manipulating *ATRAID*. *NELL-1* has a related family member, *NELL-2*. This family
354 member has been the subject of high profile studies in the field of axon guidance (52). It is
355 unknown whether *ATRAID* signals to *NELL-2* and if so what role it may play in the brain.

356
357 There are several limitations of our study. 1) Because we used a global knockout strategy with
358 *Atraid*, we can't definitively conclude it is required in vivo in osteoclasts – the target cell type for
359 the N-BPs; 2) We identified *ATRAID* in screening in leukemia cells, not in osteoclasts.

360 Therefore, there it is possible a screen in a cell type more relevant to the N-BPs would yield
361 additional genes important to bone; 3) There are relatively modest numbers of DNA samples in
362 existence from ONJ and AFF patients. More samples need to be collected and analyzed to
363 further test our findings as identifying those patients who might experience these consequences
364 when taking N-BPs is of paramount importance.

365

366 **MATERIALS AND METHODS**

367 **Study design.** The objective of this study was to identify and subsequently characterize factors
368 involved in the on- and off-target effects of the osteoporosis drugs, nitrogen-containing
369 bisphosphonates (N-BPs). To address this, we performed a genome-wide haploid cell screen
370 and identified the gene *ATRAID*. To assess the cellular role of *ATRAID* in the response to N-
371 BPs, we treated a variety of cell lines including human 293T and KBM7 cells, murine
372 macrophage RAW 264.7 cells differentiated into osteoclasts and primary cells derived from
373 mice, with the N-BPs (including alendronate and zoledronate) or other drugs and assessed cell
374 viability/growth/fitness by measuring cellular ATP, as well as protein prenylation by immunoblot.
375 These analyses established that *ATRAID* is required for the cellular responses to N-BPs. We
376 investigated the in vivo role of *ATRAID* by utilizing two mouse models of osteoporosis
377 (ovariectomies on 3.5-month old female mice as a model of post-menopausal osteoporosis
378 (OVX), and 18-month old male mice as a model for senile osteoporosis) treated with
379 alendronate. The effects on wildtype and *Atraid*^{KO} mice were assessed by profiling bone
380 structure using micro-computed tomography (μ CT) (OVX, senile: n = 6-11, n = 5-8), strength
381 using a three-point bending assay (OVX: n = 6-11), histomorphometry using TRAP staining and
382 double-labeling (OVX, senile: n = 5-7, n = 4-7), and serum bone proteins using ELISA (OVX, n =
383 8-13). These analyses established that *ATRAID* is required for the organismal responses to N-
384 BPs. To translate our findings to humans, we integrated clinical and unbiased genome-scale

385 molecular data in patients treated with N-BPs, including patients that experienced atypical
386 femoral fractures or osteonecrosis of the jaw while being treated with N-BPs. These analyses
387 established that ATRAID is potentially important for N-BP responses in humans. For our animal
388 studies, mice were randomized to treatment groups, and subsequent analyses were blinded to
389 the extent possible. All experiments involving mice were performed with protocols approved by
390 the Harvard and Washington University Animal Studies Committees. The details of study
391 design, sample sizes, experimental replicates, and statistics are provided in the corresponding
392 figures, figure legends, data files, and Material and Methods.

393

394 **Statistical analysis.** Unless otherwise specified, group means were compared by one-tailed
395 student's *t* test for unpaired samples. Data on repeated measures were analyzed by ANOVA,
396 followed by a post-hoc multiple Holm–Sidak method *t*-test. All data are expressed as the mean
397 \pm s.d with numbers of samples indicated in figure legends. *P* values are indicated in each figure
398 legend, and values less than 0.05 were considered significant (alpha) with \geq 80% power, unless
399 indicated otherwise. We estimated the cohort sizes we would need for this study based on our
400 prior study which involved a similar experimental paradigm in using bisphosphonates and the
401 ovariectomy (OVX) osteoporosis model in BL/6 mice (32). All code used to generate statistics
402 and correlations for this project can be found at <https://github.com/tim-peterson/ATRAID> (DOI:
403 10.5281/zenodo.3739576).

404

405 SUPPLEMENTARY MATERIALS

406 Materials and Methods

407 **Fig. S1. ATRAID is required for the cellular responses to nitrogen-containing**
408 **bisphosphonates.**

409 **Fig. S2. Generation and skeletal characterization of *Atraid*^{KO} mice.**

410 **Fig. S3. *Atraid* is required cell-autonomously for the effects of N-BP on osteoclasts in two**
411 **models of osteoporosis.**

412 **Table S1. Results of haploid genomic screen for genes required for the response to**
413 **alendronate.**

414 **Data file S1. Statistics for *Atraid*^{KO} mice basal characterization, and statistics for bone**
415 **structure, strength of ovariectomized wildtype and *Atraid*^{KO} animals treated with**
416 **alendronate.**

417 **Data file S2. Statistics for bone histomorphometry and serum bone proteins in**
418 **ovariectomized and senile wildtype and *Atraid*^{KO} animals treated with alendronate.**

419 **Data file S3. Gene expression, sequencing, and growth phenotype data for ONJ, DTC,**
420 **AFF and CRISPRi and CRISPRa studies.**

421

422 REFERENCES

- 423 1. M. J. Favus, Bisphosphonates for osteoporosis. *N Engl J Med* **363**, 2027-2035 (2010).
- 424 2. C. J. Rosen, Clinical practice. Postmenopausal osteoporosis. *N Engl J Med* **353**, 595-
425 603 (2005).
- 426 3. R. Coleman, The use of bisphosphonates in cancer treatment. *Ann N Y Acad Sci* **1218**,
427 3-14 (2011).
- 428 4. N. B. Watts, D. L. Diab, Long-term use of bisphosphonates in osteoporosis. *J Clin*
429 *Endocrinol Metab* **95**, 1555-1565 (2010).
- 430 5. Y. Bi, Y. Gao, D. Ehirchiou, C. Cao, T. Kikuri, A. Le, S. Shi, L. Zhang, Bisphosphonates
431 cause osteonecrosis of the jaw-like disease in mice. *Am J Pathol* **177**, 280-290 (2010).
- 432 6. S. Khosla, J. A. Cauley, J. Compston, D. P. Kiel, C. Rosen, K. G. Saag, E. Shane,
433 Addressing the Crisis in the Treatment of Osteoporosis: A Path Forward. *J Bone Miner*
434 *Res*, (2016).

- 435 7. S. Jha, Z. Wang, N. Laucis, T. Bhattacharyya, Trends in Media Reports, Oral
436 Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis. *J*
437 *Bone Miner Res* **30**, 2179-2187 (2015).
- 438 8. A. A. Reszka, G. A. Rodan, Nitrogen-containing bisphosphonate mechanism of action.
439 *Mini Rev Med Chem* **4**, 711-719 (2004).
- 440 9. V. Breuil, F. Cosman, L. Stein, W. Horbert, J. Nieves, V. Shen, R. Lindsay, D. W.
441 Dempster, Human osteoclast formation and activity in vitro: effects of alendronate. *J*
442 *Bone Miner Res* **13**, 1721-1729 (1998).
- 443 10. Z. Zimolo, G. Wesolowski, G. A. Rodan, Acid extrusion is induced by osteoclast
444 attachment to bone. Inhibition by alendronate and calcitonin. *J Clin Invest* **96**, 2277-2283
445 (1995).
- 446 11. D. E. Hughes, K. R. Wright, H. L. Uy, A. Sasaki, T. Yoneda, G. D. Roodman, G. R.
447 Mundy, B. F. Boyce, Bisphosphonates promote apoptosis in murine osteoclasts in vitro
448 and in vivo. *J Bone Miner Res* **10**, 1478-1487 (1995).
- 449 12. Z. Yu, L. E. Surface, C. Y. Park, M. A. Horlbeck, G. A. Wyant, M. Abu-Remaileh, T. R.
450 Peterson, D. M. Sabatini, J. S. Weissman, E. K. O'Shea, Identification of a transporter
451 complex responsible for the cytosolic entry of nitrogen-containing-bisphosphonates. *Elife*
452 **7**, (2018).
- 453 13. J. E. Carette, C. P. Guimaraes, M. Varadarajan, A. S. Park, I. Wuethrich, A. Godarova,
454 M. Kotecki, B. H. Cochran, E. Spooner, H. L. Ploegh, T. R. Brummelkamp, Haploid
455 genetic screens in human cells identify host factors used by pathogens. *Science* **326**,
456 1231-1235 (2009).
- 457 14. A. J. Roelofs, K. Thompson, F. H. Ebetino, M. J. Rogers, F. P. Coxon, Bisphosphonates:
458 molecular mechanisms of action and effects on bone cells, monocytes and
459 macrophages. *Curr Pharm Des* **16**, 2950-2960 (2010).

- 460 15. F. Zhu, W. Yan, Z. L. Zhao, Y. B. Chai, F. Lu, Q. Wang, W. D. Peng, A. G. Yang, C. J.
461 Wang, Improved PCR-based subtractive hybridization strategy for cloning differentially
462 expressed genes. *Biotechniques* **29**, 310-313 (2000).
- 463 16. S. Bashiardes, R. Veile, M. Allen, C. A. Wise, M. Dobbs, J. A. Morcuende, L.
464 Szappanos, J. A. Herring, A. M. Bowcock, M. Lovett, SNTG1, the gene encoding
465 gamma1-syntrophin: a candidate gene for idiopathic scoliosis. *Hum Genet* **115**, 81-89
466 (2004).
- 467 17. Y. Z. Liu, S. G. Wilson, L. Wang, X. G. Liu, Y. F. Guo, J. Li, H. Yan, P. Deloukas, N.
468 Soranzo, U. Chinappen-Horsley, A. Cervino, F. M. Williams, D. H. Xiong, Y. P. Zhang, T.
469 B. Jin, S. Levy, C. J. Papasian, B. M. Drees, J. J. Hamilton, R. R. Recker, T. D. Spector,
470 H. W. Deng, Identification of PLCL1 gene for hip bone size variation in females in a
471 genome-wide association study. *PLoS One* **3**, e3160 (2008).
- 472 18. E. Shimizu, J. Tamasi, N. C. Partridge, Alendronate affects osteoblast functions by
473 crosstalk through EphrinB1-EphB. *J Dent Res* **91**, 268-274 (2012).
- 474 19. G. Yang, F. Yu, H. Fu, F. Lu, B. Huang, L. Bai, Z. Zhao, L. Yao, Z. Lu, Identification of
475 the distinct promoters for the two transcripts of apoptosis related protein 3 and their
476 transcriptional regulation by NFAT and NFkappaB. *Mol Cell Biochem* **302**, 187-194
477 (2007).
- 478 20. <http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index>.
- 479 21. R. G. Russell, Bisphosphonates: the first 40 years. *Bone* **49**, 2-19 (2011).
- 480 22. K. Thompson, M. J. Rogers, F. P. Coxon, J. C. Crockett, Cytosolic entry of
481 bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis.
482 *Mol Pharmacol* **69**, 1624-1632 (2006).
- 483 23. W. C. Skarnes, B. Rosen, A. P. West, M. Koutsourakis, W. Bushell, V. Iyer, A. O. Mujica,
484 M. Thomas, J. Harrow, T. Cox, D. Jackson, J. Severin, P. Biggs, J. Fu, M. Nefedov, P. J.

- 485 de Jong, A. F. Stewart, A. Bradley, A conditional knockout resource for the genome-wide
486 study of mouse gene function. *Nature* **474**, 337-342 (2011).
- 487 24. M. L. Bouxsein, S. K. Boyd, B. A. Christiansen, R. E. Guldborg, K. J. Jepsen, R. Muller,
488 Guidelines for assessment of bone microstructure in rodents using micro-computed
489 tomography. *J Bone Miner Res* **25**, 1468-1486 (2010).
- 490 25. [https://cpb-us-w2.wpmucdn.com/sites.wustl.edu/dist/f/1982/files/2019/05/Understanding-](https://cpb-us-w2.wpmucdn.com/sites.wustl.edu/dist/f/1982/files/2019/05/Understanding-3pt-Bending-outcomes.pdf)
491 [3pt-Bending-outcomes.pdf](https://cpb-us-w2.wpmucdn.com/sites.wustl.edu/dist/f/1982/files/2019/05/Understanding-3pt-Bending-outcomes.pdf).
- 492 26. C. Rosenquist, C. Fledelius, S. Christgau, B. J. Pedersen, M. Bonde, P. Qvist, C.
493 Christiansen, Serum CrossLaps One Step ELISA. First application of monoclonal
494 antibodies for measurement in serum of bone-related degradation products from C-
495 terminal telopeptides of type I collagen. *Clin Chem* **44**, 2281-2289 (1998).
- 496 27. D. W. Dempster, J. E. Compston, M. K. Drezner, F. H. Glorieux, J. A. Kanis, H.
497 Malluche, P. J. Meunier, S. M. Ott, R. R. Recker, A. M. Parfitt, Standardized
498 nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the
499 report of the ASBMR Histomorphometry Nomenclature Committee. *J Bone Miner Res*
500 **28**, 2-17 (2013).
- 501 28. P. Ballanti, S. Minisola, M. T. Pacitti, L. Scarnecchia, R. Rosso, G. F. Mazzuoli, E.
502 Bonucci, Tartrate-resistant acid phosphate activity as osteoclastic marker: sensitivity of
503 cytochemical assessment and serum assay in comparison with standardized osteoclast
504 histomorphometry. *Osteoporos Int* **7**, 39-43 (1997).
- 505 29. X. Zou, J. Shen, F. Chen, K. Ting, Z. Zheng, S. Pang, J. N. Zara, J. S. Adams, C. Soo,
506 X. Zhang, NELL-1 binds to APR3 affecting human osteoblast proliferation and
507 differentiation. *FEBS Lett* **585**, 2410-2418 (2011).
- 508 30. M. Ferron, J. Wei, T. Yoshizawa, A. Del Fattore, R. A. DePinho, A. Teti, P. Ducy, G.
509 Karsenty, Insulin signaling in osteoblasts integrates bone remodeling and energy
510 metabolism. *Cell* **142**, 296-308 (2010).

- 511 31. H. A. Fleisch, Bisphosphonates: preclinical aspects and use in osteoporosis. *Ann Med*
512 **29**, 55-62 (1997).
- 513 32. M. P. Watkins, J. Y. Norris, S. K. Grimston, X. Zhang, R. J. Phipps, F. H. Ebetino, R.
514 Civitelli, Bisphosphonates improve trabecular bone mass and normalize cortical
515 thickness in ovariectomized, osteoblast connexin43 deficient mice. *Bone* **51**, 787-794
516 (2012).
- 517 33. K. Watanabe, A. Hishiya, Mouse models of senile osteoporosis. *Mol Aspects Med* **26**,
518 221-231 (2005).
- 519 34. R. Tevlin, A. McArdle, C. K. Chan, J. Pluvinage, G. G. Walmsley, T. Wearda, O.
520 Marecic, M. S. Hu, K. J. Paik, K. Senarath-Yapa, D. A. Atashroo, E. R. Zielins, D. C.
521 Wan, I. L. Weissman, M. T. Longaker, Osteoclast derivation from mouse bone marrow. *J*
522 *Vis Exp*, e52056 (2014).
- 523 35. P. Collin-Osdoby, P. Osdoby, RANKL-mediated osteoclast formation from murine RAW
524 264.7 cells. *Methods Mol Biol* **816**, 187-202 (2012).
- 525 36. N. Raje, S. B. Woo, K. Hande, J. T. Yap, P. G. Richardson, S. Vallet, N. Treister, T.
526 Hideshima, N. Sheehy, S. Chhetri, B. Connell, W. Xie, Y. T. Tai, A. Szot-Barnes, M.
527 Tian, R. L. Schlossman, E. Weller, N. C. Munshi, A. D. Van Den Abbeele, K. C.
528 Anderson, Clinical, radiographic, and biochemical characterization of multiple myeloma
529 patients with osteonecrosis of the jaw. *Clin Cancer Res* **14**, 2387-2395 (2008).
- 530 37. J. Xiang, M. A. Hurchla, F. Fontana, X. Su, S. R. Amend, A. K. Esser, G. J. Douglas, C.
531 Mudalagiriappa, K. E. Luker, T. Pluard, F. O. Ademuyiwa, B. Romagnoli, G. Tuffin, E.
532 Chevalier, G. D. Luker, M. Bauer, J. Zimmermann, R. L. Aft, K. Dembowski, K. N.
533 Weilbaecher, CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis
534 and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer. *Mol Cancer Ther*
535 **14**, 2473-2485 (2015).

- 536 38. J. L. Jiwoong Park, Sandeep Kumar, Damon T. Burrow, Nicholas L. Bean, Chris Chow,
537 Nicholas C. Jacobs, Niki Song, Sarah S. Diemar, Luke A. Gilbert, Timothy R. Peterson,
538 Using cell fitness to reduce human biases in human gene characterization. *in*
539 *preparation*, (2019).
- 540 39. M. A. Horlbeck, A. Xu, M. Wang, N. K. Bennett, C. Y. Park, D. Bogdanoff, B. Adamson,
541 E. D. Chow, M. Kampmann, T. R. Peterson, K. Nakamura, M. A. Fischbach, J. S.
542 Weissman, L. A. Gilbert, Mapping the Genetic Landscape of Human Cells. *Cell* **174**,
543 953-967 e922 (2018).
- 544 40. J. Bergholz, Z. X. Xiao, Role of p63 in Development, Tumorigenesis and Cancer
545 Progression. *Cancer Microenviron* **5**, 311-322 (2012).
- 546 41. E. L. Scheller, C. M. Baldwin, S. Kuo, N. J. D'Silva, S. E. Feinberg, P. H. Krebsbach, P.
547 C. Edwards, Bisphosphonates inhibit expression of p63 by oral keratinocytes. *J Dent*
548 *Res* **90**, 894-899 (2011).
- 549 42. S. Han, Q. Lu, N. Wang, Apr3 accelerates the senescence of human retinal pigment
550 epithelial cells. *Mol Med Rep* **13**, 3121-3126 (2016).
- 551 43. E. Lecona, O. Fernandez-Capetillo, Targeting ATR in cancer. *Nat Rev Cancer*, (2018).
- 552 44. D. Yamada, R. Perez-Torrado, G. Filion, M. Caly, B. Jammart, V. Devignot, N. Sasai, P.
553 Ravassard, J. Mallet, X. Sastre-Garau, M. L. Schmitz, P. A. Defosse, The human
554 protein kinase HIPK2 phosphorylates and downregulates the methyl-binding
555 transcription factor ZBTB4. *Oncogene* **28**, 2535-2544 (2009).
- 556 45. A. Weber, J. Marquardt, D. Elzi, N. Forster, S. Starke, A. Glaum, D. Yamada, P. A.
557 Defosse, J. Delrow, R. N. Eisenman, H. Christiansen, M. Eilers, Zbtb4 represses
558 transcription of P21CIP1 and controls the cellular response to p53 activation. *EMBO J*
559 **27**, 1563-1574 (2008).
- 560 46. J. Y. Chou, B. C. Mansfield, The SLC37 family of sugar-phosphate/phosphate
561 exchangers. *Curr Top Membr* **73**, 357-382 (2014).

- 562 47. M. K. Hytonen, M. Arumilli, A. K. Lappalainen, M. Owczarek-Lipska, V. Jagannathan, S.
563 Hundi, E. Salmela, P. Venta, E. Sarkiala, T. Jokinen, D. Gorgas, J. Kere, P. Nieminen,
564 C. Drogemuller, H. Lohi, Molecular Characterization of Three Canine Models of Human
565 Rare Bone Diseases: Caffey, van den Ende-Gupta, and Raine Syndromes. *PLoS Genet*
566 **12**, e1006037 (2016).
- 567 48. A. Guerin, L. Dupuis, R. Mendoza-Londono, in *GeneReviews((R))*, M. P. Adam, H. H.
568 Ardinger, R. A. Pagon, S. E. Wallace, L. J. H. Bean, K. Stephens, A. Amemiya, Eds.
569 (Seattle (WA), 1993).
- 570 49. X. Zou, J. Shen, F. Chen, K. Ting, Z. Zheng, S. Pang, J. N. Zara, J. S. Adams, C. Soo,
571 X. Zhang, NELL-1 binds to APR3 affecting human osteoblast proliferation and
572 differentiation. *FEBS Lett* **585**, 2410-2418 (2011).
- 573 50. J. Desai, M. E. Shannon, M. D. Johnson, D. W. Ruff, L. A. Hughes, M. K. Kerley, D. A.
574 Carpenter, D. K. Johnson, E. M. Rinchik, C. T. Culiati, Nell1-deficient mice have reduced
575 expression of extracellular matrix proteins causing cranial and vertebral defects. *Hum*
576 *Mol Genet* **15**, 1329-1341 (2006).
- 577 51. A. W. James, J. Shen, X. Zhang, G. Asatrian, R. Goyal, J. H. Kwak, L. Jiang, B. Bengs,
578 C. T. Culiati, A. S. Turner, H. B. Seim Iii, B. M. Wu, K. Lyons, J. S. Adams, K. Ting, C.
579 Soo, NELL-1 in the treatment of osteoporotic bone loss. *Nat Commun* **6**, 7362 (2015).
- 580 52. A. Jaworski, I. Tom, R. K. Tong, H. K. Gildea, A. W. Koch, L. C. Gonzalez, M. Tessier-
581 Lavigne, Operational redundancy in axon guidance through the multifunctional receptor
582 Robo3 and its ligand NELL2. *Science* **350**, 961-965 (2015).
- 583 53. J. E. Carette, C. P. Guimaraes, I. Wuethrich, V. A. Blomen, M. Varadarajan, C. Sun, G.
584 Bell, B. Yuan, M. K. Muellner, S. M. Nijman, H. L. Ploegh, T. R. Brummelkamp, Global
585 gene disruption in human cells to assign genes to phenotypes by deep sequencing. *Nat*
586 *Biotechnol* **29**, 542-546 (2011).

- 587 54. M. Jost, Y. Chen, L. A. Gilbert, M. A. Horlbeck, L. Krenning, G. Menchon, A. Rai, M. Y.
588 Cho, J. J. Stern, A. E. Prota, M. Kampmann, A. Akhmanova, M. O. Steinmetz, M. E.
589 Tanenbaum, J. S. Weissman, Combined CRISPRi/a-Based Chemical Genetic Screens
590 Reveal that Rigosertib Is a Microtubule-Destabilizing Agent. *Mol Cell* **68**, 210-223 e216
591 (2017).
- 592 55. <http://weissmanlab.ucsf.edu/CRISPR/CRISPR.html>.
- 593 56. T. R. Peterson, S. S. Sengupta, T. E. Harris, A. E. Carmack, S. A. Kang, E. Balderas, D.
594 A. Guertin, K. L. Madden, A. E. Carpenter, B. N. Finck, D. M. Sabatini, mTOR complex 1
595 regulates lipin 1 localization to control the SREBP pathway. *Cell* **146**, 408-420 (2011).
- 596 57. T. R. Peterson, M. Laplante, C. C. Thoreen, Y. Sancak, S. A. Kang, W. M. Kuehl, N. S.
597 Gray, D. M. Sabatini, DEPTOR is an mTOR inhibitor frequently overexpressed in
598 multiple myeloma cells and required for their survival. *Cell* **137**, 873-886 (2009).
- 599 58. F. A. Ran, P. D. Hsu, J. Wright, V. Agarwala, D. A. Scott, F. Zhang, Genome
600 engineering using the CRISPR-Cas9 system. *Nat Protoc* **8**, 2281-2308 (2013).
- 601 59. F. P. Coxon, M. H. Helfrich, R. Van't Hof, S. Sebt, S. H. Ralston, A. Hamilton, M. J.
602 Rogers, Protein geranylgeranylation is required for osteoclast formation, function, and
603 survival: inhibition by bisphosphonates and GGTI-298. *J Bone Miner Res* **15**, 1467-1476
604 (2000).
- 605 60. J. C. Frith, J. Monkkonen, S. Auriola, H. Monkkonen, M. J. Rogers, The molecular
606 mechanism of action of the antiresorptive and antiinflammatory drug clodronate:
607 evidence for the formation in vivo of a metabolite that inhibits bone resorption and
608 causes osteoclast and macrophage apoptosis. *Arthritis and rheumatism* **44**, 2201-2210
609 (2001).
- 610 61. M. Tsubaki, M. Komai, T. Itoh, M. Imano, K. Sakamoto, H. Shimaoka, T. Takeda, N.
611 Ogawa, K. Mashimo, D. Fujiwara, J. Mukai, K. Sakaguchi, T. Satou, S. Nishida,
612 Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast

- 613 formation through the inhibition of ERK1/2 and Akt activation. *J Biomed Sci* **21**, 10
614 (2014).
- 615 62. R. Kuhn, R. M. Torres, Cre/loxP recombination system and gene targeting. *Methods Mol*
616 *Biol* **180**, 175-204 (2002).
- 617 63. https://simple.wikipedia.org/wiki/Central_dogma_of_molecular_biology.
- 618 64. F. Schwenk, U. Baron, K. Rajewsky, A cre-transgenic mouse strain for the ubiquitous
619 deletion of loxP-flanked gene segments including deletion in germ cells. *Nucleic Acids*
620 *Res* **23**, 5080-5081 (1995).
- 621 65. C. F. Lai, S. L. Cheng, G. Mbalaviele, C. Donsante, M. Watkins, G. L. Radice, R.
622 Civitelli, Accentuated ovariectomy-induced bone loss and altered osteogenesis in
623 heterozygous N-cadherin null mice. *J Bone Miner Res* **21**, 1897-1906 (2006).
- 624 66. R. K. Fuchs, R. J. Phipps, D. B. Burr, Recovery of trabecular and cortical bone turnover
625 after discontinuation of risedronate and alendronate therapy in ovariectomized rats. *J*
626 *Bone Miner Res* **23**, 1689-1697 (2008).
- 627 67. M. R. Allen, K. Iwata, R. Phipps, D. B. Burr, Alterations in canine vertebral bone
628 turnover, microdamage accumulation, and biomechanical properties following 1-year
629 treatment with clinical treatment doses of risedronate or alendronate. *Bone* **39**, 872-879
630 (2006).
- 631 68. M. L. Bouxsein, K. S. Myers, K. L. Shultz, L. R. Donahue, C. J. Rosen, W. G. Beamer,
632 Ovariectomy-induced bone loss varies among inbred strains of mice. *J Bone Miner Res*
633 **20**, 1085-1092 (2005).
- 634 69. M. D. Willingham, M. D. Brodt, K. L. Lee, A. L. Stephens, J. Ye, M. J. Silva, Age-
635 related changes in bone structure and strength in female and male BALB/c mice. *Calcif*
636 *Tissue Int* **86**, 470-483 (2010).

- 637 70. S. K. Grimston, D. B. Goldberg, M. Watkins, M. D. Brodt, M. J. Silva, R. Civitelli,
638 Connexin43 deficiency reduces the sensitivity of cortical bone to the effects of muscle
639 paralysis. *J Bone Miner Res* **26**, 2151-2160 (2011).
- 640 71. T. A. Guise, Antitumor effects of bisphosphonates: promising preclinical evidence.
641 *Cancer Treat Rev* **34 Suppl 1**, S19-24 (2008).
- 642 72. R. Aft, M. Naughton, K. Trinkaus, M. Watson, L. Ylagan, M. Chavez-MacGregor, J. Zhai,
643 S. Kuo, W. Shannon, K. Diemer, V. Herrmann, J. Dietz, A. Ali, M. Ellis, P. Weiss, T.
644 Eberlein, C. Ma, P. M. Fracasso, I. Zoberi, M. Taylor, W. Gillanders, T. Pluard, J.
645 Mortimer, K. Weilbaecher, Effect of zoledronic acid on disseminated tumour cells in
646 women with locally advanced breast cancer: an open label, randomised, phase 2 trial.
647 *Lancet Oncol* **11**, 421-428 (2010).
- 648 73. B. M. Bolstad, R. A. Irizarry, M. Astrand, T. P. Speed, A comparison of normalization
649 methods for high density oligonucleotide array data based on variance and bias.
650 *Bioinformatics* **19**, 185-193 (2003).
- 651 74. C. V. Gentleman R, Huber W and Hahne F (2017).
- 652 75. G. K. Smyth, Linear models and empirical bayes methods for assessing differential
653 expression in microarray experiments. *Stat Appl Genet Mol Biol* **3**, Article3 (2004).
- 654 76. M. Carlson. (2016).
- 655 77. J. G. Buchan, D. M. Alvarado, G. E. Haller, C. Cruchaga, M. B. Harms, T. Zhang, M. C.
656 Willing, D. K. Grange, A. C. Braverman, N. H. Miller, J. A. Morcuende, N. L. Tang, T. P.
657 Lam, B. K. Ng, J. C. Cheng, M. B. Dobbs, C. A. Gurnett, Rare variants in FBN1 and
658 FBN2 are associated with severe adolescent idiopathic scoliosis. *Hum Mol Genet* **23**,
659 5271-5282 (2014).
- 660 78. C. Cruchaga, C. M. Karch, S. C. Jin, B. A. Benitez, Y. Cai, R. Guerreiro, O. Harari, J.
661 Norton, J. Budde, S. Bertelsen, A. T. Jeng, B. Cooper, T. Skorupa, D. Carrell, D. Levitch,
662 S. Hsu, J. Choi, M. Ryten, J. Hardy, D. Trabzuni, M. E. Weale, A. Ramasamy, C. Smith,

- 663 C. Sassi, J. Bras, J. R. Gibbs, D. G. Hernandez, M. K. Lupton, J. Powell, P. Forabosco,
664 P. G. Ridge, C. D. Corcoran, J. T. Tschanz, M. C. Norton, R. G. Munger, C. Schmutz, M.
665 Leary, F. Y. Demirci, M. N. Bamne, X. Wang, O. L. Lopez, M. Ganguli, C. Medway, J.
666 Turton, J. Lord, A. Braae, I. Barber, K. Brown, P. Passmore, D. Craig, J. Johnston, B.
667 McGuinness, S. Todd, R. Heun, H. Kolsch, P. G. Kehoe, N. M. Hooper, E. R. Vardy, D.
668 M. Mann, S. Pickering-Brown, N. Kalsheker, J. Lowe, K. Morgan, A. David Smith, G.
669 Wilcock, D. Warden, C. Holmes, P. Pastor, O. Lorenzo-Betancor, Z. Brkanac, E. Scott,
670 E. Topol, E. Rogaeva, A. B. Singleton, M. I. Kamboh, P. St George-Hyslop, N. Cairns, J.
671 C. Morris, J. S. Kauwe, A. M. Goate, Rare coding variants in the phospholipase D3 gene
672 confer risk for Alzheimer's disease. *Nature* **505**, 550-554 (2014).
- 673 79. P. Krawitz, C. Rodelsperger, M. Jager, L. Jostins, S. Bauer, P. N. Robinson, Microindel
674 detection in short-read sequence data. *Bioinformatics* **26**, 722-729 (2010).
- 675 80. A. McKenna, M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis, A. Kernysky, K.
676 Garimella, D. Altshuler, S. Gabriel, M. Daly, M. A. DePristo, The Genome Analysis
677 Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.
678 *Genome Res* **20**, 1297-1303 (2010).
- 679 81. G. A. Van der Auwera, M. O. Carneiro, C. Hartl, R. Poplin, G. Del Angel, A. Levy-
680 Moonshine, T. Jordan, K. Shakir, D. Roazen, J. Thibault, E. Banks, K. V. Garimella, D.
681 Altshuler, S. Gabriel, M. A. DePristo, From FastQ data to high confidence variant calls:
682 the Genome Analysis Toolkit best practices pipeline. *Curr Protoc Bioinformatics* **43**, 11
683 10 11-33 (2013).
- 684 82. M. Lek, K. J. Karczewski, E. V. Minikel, K. E. Samocha, E. Banks, T. Fennell, A. H.
685 O'Donnell-Luria, J. S. Ware, A. J. Hill, B. B. Cummings, T. Tukiainen, D. P. Birnbaum, J.
686 A. Kosmicki, L. E. Duncan, K. Estrada, F. Zhao, J. Zou, E. Pierce-Hoffman, J. Berghout,
687 D. N. Cooper, N. Deflaux, M. DePristo, R. Do, J. Flannick, M. Fromer, L. Gauthier, J.
688 Goldstein, N. Gupta, D. Howrigan, A. Kiezun, M. I. Kurki, A. L. Moonshine, P. Natarajan,

689 L. Orozco, G. M. Peloso, R. Poplin, M. A. Rivas, V. Ruano-Rubio, S. A. Rose, D. M.
690 Ruderfer, K. Shakir, P. D. Stenson, C. Stevens, B. P. Thomas, G. Tiao, M. T. Tusie-
691 Luna, B. Weisburd, H. H. Won, D. Yu, D. M. Altshuler, D. Ardissino, M. Boehnke, J.
692 Danesh, S. Donnelly, R. Elosua, J. C. Florez, S. B. Gabriel, G. Getz, S. J. Glatt, C. M.
693 Hultman, S. Kathiresan, M. Laakso, S. McCarroll, M. I. McCarthy, D. McGovern, R.
694 McPherson, B. M. Neale, A. Palotie, S. M. Purcell, D. Saleheen, J. M. Scharf, P. Sklar,
695 P. F. Sullivan, J. Tuomilehto, M. T. Tsuang, H. C. Watkins, J. G. Wilson, M. J. Daly, D.
696 G. MacArthur, C. Exome Aggregation, Analysis of protein-coding genetic variation in
697 60,706 humans. *Nature* **536**, 285-291 (2016).

698

699 **ACKNOWLEDGMENTS**

700 We thank members of the Peterson and E. O'Shea laboratories for helpful discussions,
701 especially C. Chow and K. Li (Peterson), and A. R. Subramaniam, C. Chidley, and A.
702 Puszynska for illustrations (O'Shea). We thank M. Bouxsein and D. Brooks (Beth Israel
703 Deaconess Medical Center), and D. Lieb, Y. Kim, and M. Silva (Washington University School
704 of Medicine) for bone structure and function analysis. We thank K. Nagano and R. Baron
705 (Harvard School of Dental Medicine), Y. Iwamoto (Massachusetts General Hospital) and D.
706 Novack, G. London, K. Hyrc, and C. Idleburg for histology, histomorphometry, and imaging
707 (Washington University School of Medicine). We thank L. Gilbert (University of California San
708 Francisco) for assistance on the CRISPRi/a screening protocol. **Funding:** This work was
709 supported by grants from the NIH (CA103866 and AI047389 to D.M.S., HD070394 to B.H.L.)
710 and Department of Defense (W81XWH-07-0448 to D.M.S.); awards from the W.M. Keck
711 Foundation and the LAM (lymphangioliomyomatosis) Foundation to D.M.S.; Rolanette and
712 Berdon Lawrence Bone Disease Program of Texas and BCM Center for Skeletal Medicine and
713 Biology and NIDDK training grant 5T32DK060445-10 to A.R.; Shriners Hospitals for Children
714 and Merck Sharp & Dohme to S.M.; Fellowship from the Jane Coffin Childs Foundation, and

715 NIH/NIA K99/R00 AG047255, NIH/NIAMS R01 AR073017, and NIH/NIAMS P30 AR057235 to
716 T.R.P.; NIH/NIAMS K99 AR073903 to L.E.S. D.M.S. is an investigator of the Howard Hughes
717 Medical Institute. NCI 2RO1CA129933 to D.A.H., who is also investigator of the Howard
718 Hughes Medical Institute and a F30 NIH training grant to C.L.C. **Author Contributions:** T.R.P.
719 and L.E.S. designed the study. D.T.B. performed the co-culture experiments and senile
720 osteoporosis mouse studies. L.E.S. and J.L. performed the *ATRAID* variant studies. J.P., A.R.,
721 and Z.Y. performed viability assays. S.K. and L.E.S. performed immunoblots. Y.B., B.H.L.,
722 D.T.B. and N.S. conducted analysis of both basal and OVX mouse studies. C.L., F.W., and
723 T.R.P. performed statistical analysis for the patient gene expression and mouse studies. T.R.P.
724 performed the statistical analysis for the CRISPRi/a screens. S.M., J.C.B., M.M., M.S., M.H.,
725 S.D., V.N.B., R.C., M.J.G., C.M.M., W.M.R., C.A.G., and K.D. performed the exome sequencing
726 on the AFF patients. G.H. and C.C.G. performed statistical analysis for the exome sequencing
727 of the AFF patients. D.A.H, C.L.C., K.M.S., N.R., T.B.D., and T.R.P. performed the exome
728 sequencing on the ONJ patients. G.H. performed the statistical analysis for the exome
729 sequencing of the ONJ patients. M.V., K.B., J.E.C., T.R.B., D.M.S., and J.L. performed and/or
730 provided assistance with the cell-based genomic screening. T.R.P., J.P., and L.E.S. wrote the
731 paper. **Competing Interests:** *ATRAID*, *SNTG1*, *EPHB1*, and *PLCL1*, the genes identified here,
732 are part of a Whitehead–Harvard patent on which T.R.P., T.R.B., and D.M.S. are inventors
733 (US8748097B1). No authors received consulting fees related to this work. **Data and materials**
734 **availability:** All data associated with this study are present in the paper, the Supplementary
735 Materials, or will be available at NCBI BioProject ID: PRJNA624650. Shared reagents are
736 subject to a materials transfer agreement.

737

738 **FIGURE CAPTIONS**

739 **Fig. 1. *ATRAID* is required for molecular responses to nitrogen-containing**
740 **bisphosphonates. (A)** Schematic of haploid mutagenesis screening pipeline. Sequencing-
741 based identification of gene-trap insertion sites in alendronate-resistant human haploid KBM7
742 cells. Genomic DNA for sequencing was obtained from mutagenized KBM7 cells grown for four
743 weeks post-treatment with alendronate (165 μ M). **(B)** Sequencing-based identification of gene-
744 trap insertion sites in alendronate-resistant cells. N=number of unique insertions within the
745 stated gene locus. False discovery rate corrected (FDR) *P*-values for *ATRAID*= 7.02×10^{-45} ,
746 *PLCL1*= 1.02×10^{-04} , *EPHB1*= 2.05×10^{-04} , *SNTG1*= 1.84×10^{-03} . *P*-values represent enrichment in
747 alendronate-treated versus vehicle treated cells. **(C)** Schematic representation of structural
748 features of human *ATRAID* protein and its mouse and frog orthologues. **(D)** Cell viability in wild-
749 type control and *ATRAID*-deficient cells exogenously expressing or not expressing *ATRAID*
750 cDNA. Cells were treated with alendronate (60 μ M) and analyzed for cell viability. Cell viability
751 was determined by measuring cellular ATP and is expressed as a ratio of that compared with
752 untreated cells. Error bars indicate the standard deviation for n=4 (biological replicates). N.S.,
753 not significant; **P* < 0.05, student's *t*-test. v2, variant 2 (NM_080592.3); v3, variant 3
754 (NM_001170795.1) of the *ATRAID* gene, respectively. **(E)** Chemical structures for nitrogen-
755 containing bisphosphonates (N-BPs) or non-nitrogen-containing bisphosphonates (BP). KBM7
756 cell viability in *ATRAID*-deficient (*ATRAID*_GT1 and *ATRAID*_GT2) and control (wild-type)
757 KBM7 cells upon treatment with nitrogen-containing bisphosphonates (N-BPs) or non-nitrogen-
758 containing bisphosphonates (BP). All cells were treated with the indicated concentration of the
759 indicated N-BP (alendronate, zoledronate), BP (etidronate, tiludronate) for 72 hours. Cell
760 viability was determined by measuring cellular ATP and is expressed as a ratio of that
761 compared with untreated cells. All measurements were performed in quadruplicate (biological
762 replicates). **P* < 0.05, student's *t*-test. **(F)** Immunoblots of cell lysates from *ATRAID*-deficient
763 and *ATRAID* v3-reconstituted HEK-293T cells treated with the indicated dose of alendronate for

764 24 hours. Equal amounts of protein were loaded in each lane. This experiment was repeated
765 three times (biological replicates) and was consistent all three times. *non-specific band.

766

767 **Fig. 2. *Atraid* is required for organismal responses to nitrogen-containing**

768 **bisphosphonates. (A)** Schematic of mouse menopausal bone loss model – bilateral

769 ovariectomy (OVX). Saline or 100 µg/kg/week alendronate was administered concurrent with

770 OVX or a sham procedure. After four weeks, mice were euthanized and bones and serum were

771 extracted and analyzed. **(B)** Representative µCT reconstructions of femoral trabecular bone

772 from 4-month-old litter-matched derived, wild-type, *Atraid* WT (+/+), and KO (-/-), female mice

773 that were either ovariectomized (OVX) or sham operated (Sham), treated with either vehicle

774 (saline) (+OVX), or alendronate (+OVX+ALN) for four weeks. **(C-F)** Ovariectomized WT and

775 *Atraid* KO mice and their bone microstructural responses to alendronate. Femur cortical (C, D)

776 and trabeculae (E, F) regions were analyzed by µCT. Each circle represents an individual

777 animal. Circles offset to the right represent unique animals with similar values to those of

778 another animal (offset for visual clarity). N=6-11 mice (3.5 month old) per group. * $P < 0.01$, #

779 indicates $0.01 < P < 0.05$, student's *t*-test and red line indicates mean. **(G-H)** Ovariectomized WT

780 and *Atraid* KO mice and their bone strength responses to alendronate. Stiffness (G) and yield

781 load (H) were analyzed by three-point bending test. Each circle represents an individual animal.

782 Circles offset to the right represent unique animals with similar values to those of another animal

783 (offset for visual clarity). N=6-11 mice per group. * $P < 0.01$, # $0.01 < P < 0.05$, N.S., indicates not

784 significant, student's *t*-test, and red line indicates mean.

785

786 **Fig. 3. *Atraid* is required cell-autonomously for N-BP inhibition of osteoclast**

787 **preylation.(A)** CTX-I, a serum marker of osteoclast activity, was measured in WT and *Atraid*^{KO}

788 ovariectomized mice with or without alendronate treatment by ELISA. Each circle represents an

789 individual animal. Circles offset to the right represent unique animals with similar values to those

790 of another animal (offset for visual clarity). N=8-13 mice per group. * $P < 0.05$, student's t -test.

791 **(B)** Osteoclast histomorphometric responses in WT and *Atraid*^{KO} ovariectomized mice with or
792 without alendronate treatment. Osteoclast surface to bone surface ratio (Oc.S/BS) was
793 determined by Tartrate Acid Phosphatase (TRAP)-assay reactivity. Each circle represents an
794 individual animal. Circles offset to the right represent unique animals with similar values to those
795 of another animal (offset for visual clarity). N=5-7 mice per group. * $P < 0.05$, n.s. indicates not
796 significant, student's t -test, and red line indicates mean. **(C)** Quantitative PCR to examine
797 mRNA expression of markers of osteoclast differentiation, *Ctsk*, *Tnfrsf11a* (*RANK*), *Acp5*
798 (*TRAP*), in wild-type (WT) and *Atraid*^{KO} M-CSF-expanded bone marrow macrophages (BMMs)
799 differentiated with *RANKL* to osteoclasts. Expression is normalized to wild-type, undifferentiated
800 BMM cells, using *Actb* and *Rplp0* as control genes. Error bars represent the standard deviation
801 of technical triplicate reactions. **(D)** Percent of Annexin-V positive cells after a 48 hour
802 alendronate treatment of WT and *Atraid*^{KO} BMMs differentiated into osteoclasts. Annexin V
803 staining was assessed using flow cytometry. Each circle represents osteoclasts derived from an
804 individual animal (split for treatment with 0, 10 μ M, 30 μ M alendronate). Red line indicates
805 mean. * $P < 0.05$, N.S. indicates not significant, student's t -test. **(E)** Percent of Annexin-V
806 positive cells after a 48 hour alendronate treatment (0, 30 μ M, 80 μ M) in wild-type and *Atraid*^{KO}
807 differentiated RAW 264.7 osteoclasts. Annexin V staining was assessed using flow cytometry.
808 Error bars represent the standard deviation of n=3 experiments (biological replicates), * $P < 0.05$,
809 student's t -test. **(F)** Immunoblots of cell lysates of RAW wild-type (WT) and *Atraid*^{KO} (KO) cells,
810 and RAW 264.7-derived osteoclasts treated with alendronate for 48 hours. Top panel:
811 immunoblot specific to the unphosphorylated version of Rap1a. Bottom panel: Gapdh, serving as a
812 loading control. Alendronate concentrations were 0, 20 μ M, 80 μ M. **(G)** Representative image of
813 a six-well dish co-culture of equal numbers of mouse primary osteoblasts and osteoclasts of the
814 indicated genotypes with or without the indicated doses of alendronate (ALN) for four days. The
815 experiment was performed three independent times with a similar result. Red staining reflects

816 TRAP-assay reactivity. **(H)** Image analysis of the samples in (G). Error bars represent the
817 standard deviation of $n=3$ independent images (technical replicates). $*P < 0.01$, N.S. indicates
818 not significant, student's t -test.

819

820 **Fig. 4. *ATRAID* as a potential genetic factor for altered responses to nitrogen-containing**

821 **bisphosphonates in patients. (A)** Genome-wide studies of N-BP responsiveness in patients

822 vs. cells. The outcomes considered from human studies involving N-BPs are: osteonecrosis of

823 the jaw (ONJ), breast cancer bone marrow micrometastases [disseminated tumor cells (DTC)],

824 and atypical femoral fractures (AFF). *ATRAID*, *ATR*, *ZBTB4* are statistically significant hits (FDR

825 corrected $P < 0.05$) in N-BP cell-based CRISPRi/a screening, differentially expressed in both

826 gene expression datasets (ONJ and DTC), and possess rare multiple non-synonymous coding

827 variants in AFF and ONJ cases but not controls. These three genes are visualized as the Venn

828 diagram of overlap of lists of genes that met the following criteria: significant alendronate

829 CRISPRi, zoledronate CRISPRi, or alendronate CRISPRa hits with absolute value of rho growth

830 phenotype values ≥ 0.30 and $P \leq 0.05$ (1335 out of 15828 genes) (12, 38); differentially

831 expressed N-BP in ONJ + DTC (774 out of 18415 for ONJ (36) and 20492 for DTC (37);

832 multiple coding variant(s) in AFF and ONJ cases and not controls (1252 out of 11659 genes)

833 (data as part of this study). **(B)** Patient genetic data for *ATRAID*. Raw expression values were

834 normalized to 1 to fit on a comparable Y axis. $*P < 0.05$, moderated t -test. N.S. indicates not

835 significant. "X"-enriched refers to the fold-enrichment of the allele compared with a population

836 with a similar genetic background as the cases. For example, for *ATRAID*, the D5G variant is

837 present in 2 out of 27 AFF patients. Though this allele wasn't detected in the 11 control








838 samples, it is present in a population of European Americans (EA) and Asian Americans (AA)






839 that is representative of the study population at a prevalence of 0.0131. Therefore, the D5G


840 allele is $(2/27) / 0.0131 = 5.66X$ enriched in cases compared to the EA/AA population. "v3" and

841 "v2" refer to isoforms of the *ATRAID* gene. A simple binomial test was used to calculate the

842 significance of each variant. * $P < 0.05$. **(C)** Quantitative PCR to examine *ATRAID* mRNA
843 expression in wild-type, *ATRAID*-deficient, and low *ATRAID* expressing cells. Error bars
844 represent the standard deviation of technical triplicate reactions. Expression was normalized to
845 WT cells using *RPLP0* and *TBP* as controls. * indicates $P < 0.05$, student's *t*-test. **(D)** Cell viability
846 in wild-type, *ATRAID*-deficient, and low *ATRAID* expressing cells. Cells were treated with the
847 indicated doses of alendronate and analyzed for cell viability. Cell viability was determined by
848 measuring cellular ATP and is expressed as a ratio of that compared with untreated cells. Error
849 bars indicate the standard deviation for $n=4$ (biological replicates). N.S., not significant; * and #
850 indicate $P < 0.05$ for the indicated cell lines, student's *t*-test. **(E)** Immunoblot (IB) of wild-type and
851 D5G/G32R variant *ATRAID*-V5 tagged proteins. Mutant or wild-type *ATRAID* v2 and v3 were
852 stably introduced into *ATRAID*-deficient HEK-293T cells. **(F)** Cell viability in wild-type vs.
853 D5G/G32R variant cells. Cells were treated with the indicated doses of alendronate and
854 analyzed for cell viability. Cell viability was determined by measuring cellular ATP and is
855 expressed as a ratio of that compared with untreated cells. Error bars indicate the standard
856 deviation for $n=4$ (biological replicates). N.S., not significant; * $P < 0.05$, student's *t*-test.
857
858








A

genome-wide studies involving N-BPs



CRISPRi/a = cell-based drug response screen
 WES = whole exome sequencing
 N-BPs = nitrogen-containing bisphosphonates
 ONJ = osteonecrosis of the jaw
 DTC = bone marrow disseminated tumor cells
 AFF = atypical femoral fractures

WES+CRISPRi/a

64 genes

WES+gene expr.

49 genes

CRISPRi/a+gene expr.

76 genes







WES+CRISPRi/a

+gene expr.

ATR

ATRAID

ZBTB4

**B****C****D****E****F**

SUPPLEMENTARY MATERIALS

Materials and Methods

Fig. S1. *ATRAID* is required for the cellular responses to nitrogen-containing bisphosphonates.

Fig. S2. Generation and skeletal characterization of *Atraid*^{KO} mice.

Fig. S3. *Atraid* is required cell-autonomously for the effects of N-BP on osteoclasts in two models of osteoporosis.

Table S1. Results of haploid genomic screen for genes required for the response to alendronate.

Data file S1. Statistics for *Atraid*^{KO} mice basal characterization, and statistics for bone structure, strength of ovariectomized wildtype and *Atraid*^{KO} animals treated with alendronate.

Data file S2. Statistics for bone histomorphometry and serum bone proteins in ovariectomized and senile wildtype and *Atraid*^{KO} animals treated with alendronate.

Data file S3. Gene expression, sequencing, and growth phenotype data for ONJ, DTC, AFF and CRISPRi and CRISPRa studies.

MATERIALS AND METHODS

Materials. Reagents were obtained from the following sources: antibodies to Rap1a (SC-1482, 1:100) from Santa Cruz Biotechnology; anti-HDJ-2/DNAJ Ab-1, Clone: KA2A5.6 (cat.# MS-225-P0, 1:2000), anti-V5 (cat.# R960-25, 1:1000), and GAPDH (14C10) Rabbit mAb (cat.# 2118S, 1:1000) from Fisher Scientific; rabbit polyclonal and monoclonal antibodies to PARP (cat.# 9532) from Cell Signaling Technology; FuGENE 6 (cat.# E2691) and Complete Protease Cocktail (cat.# 11836170001) from Roche; alendronate (cat.# 1012780-200MG), etidronate (cat.# P5248-10MG), tiludronate (cat.# T4580-50MG), Acid Phosphatase Leukocyte (TRAP) kit

(cat.# 387A-1KT), SYBR Green JumpStart Taq ReadyMix (cat.# 4309155), calcein (cat.# C0875-5G), FLAG M2 affinity agarose beads (Cat.# M2220), and anti-FLAG antibody (F3165), 3X FLAG peptide (F4799), β -glycerophosphate (cat.# 50020), ascorbic acid (cat.# A5960), RANKL (cat.# R0525), M-CSF (cat.# M9170), dexamethasone (cat.# D4902), vitamin D3 (cat.# D1530), and alizarin red (cat.# A3882-1G) from Sigma-Aldrich. Zoledronic acid (zoledronate, cat.# M 1875) from Moravek; IMDM Glutamax, α -MEM, RPMI, SuperScript II Reverse Transcriptase, Platinum Pfx, Platinum Taq DNA Polymerase and inactivated fetal calf serum (IFS) from Invitrogen; NEBNext Ultra II Q5 Master Mix (cat.# M0544L), Sal I-HF (cat.# R3138L), Not I-HF (cat.# R3189L), BstXI (cat.# R0113L), BpI (cat.# R0585L) from New England Biolabs; NucleoSpin Blood DNA isolation kit (cat.# 740950.50) from Macherey Nagel.

Cell lines and cell culture. KBM7 cell lines were cultured in IMDM with 10% FBS. K562 cell lines were cultured in Iscove's Modified Dulbecco's Medium (IMDM) or Roswell Park Memorial Institute (RPMI) medium with 10 mM Glutamine with 10% FBS. HEK-293T cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) with 10% FBS. RAW264.7 and primary mouse cells were cultured as described below.

Haploid genetic screening. The genetic selection with alendronate was performed on 100 million mutagenized KBM7 cells (53). Cells were exposed to 165 μ M alendronate and allowed to recover for 4 weeks before harvesting the surviving cells and isolating genomic DNA. Analysis of the screen was performed essentially as described previously (53). In brief, the sequences flanking retroviral insertion sites were determined using inverse PCR followed by Illumina sequencing. After mapping these sequences to the human genome, we counted the number of inactivating mutations (mutations in the sense orientation or present in exon) per individual Refseq-annotated gene as well as the total number of inactivating insertions for all Refseq-annotated genes. For each gene, statistical enrichment was calculated by comparing how often

that gene was mutated in the drug-treated population with how often the gene carries an insertion in the untreated control dataset. For each gene, the P -value (corrected for false discovery rate) was calculated using the one-sided Fisher exact test (table S1).

CRISPRi/a genetic screening. We sought to improve the gene coverage in the zoledronate CRISPRi screen we previously reported because we observed it was relatively under-sampled compared to other CRISPRi/a screens we and others had performed (12, 54). We isolated genomic DNA from biological replicate samples from our zoledronate screen and adapted the Weissman lab library preparation protocol (55) with the following two changes to achieve greater sgRNA coverage: i) we increased the input genomic DNA from 0.5 μ g to 10 μ g of per PCR reaction; and ii) we switched from Phusion to NEBNext Ultra II Q5 PCR enzyme. Preparing the library with these modifications didn't change the top hits but it resulted in greater number of sgRNAs for each gene being detected and more robust overlap of the gene scores with our other CRISPRi/a screens with N-BPs. Data analysis including statistical calculations for the screens using the v2 CRISPRi/a libraries were performed as described in detail in our previous work by Zhou et al. (12).

cDNA manipulations and mutagenesis. The cDNAs for *ATRAID* were cloned from a human R4 cell line cDNA library. For expression studies, all cDNAs were amplified by PCR and the products were subcloned into the Sal 1 and Not 1 sites of pRK5 or pMSCV (56). The controls, *metap2* and *tubulin*, were previously described (57). All constructs were verified by DNA sequencing. To generate the 293T *ATRAID_KO* expressing *ATRAID-FLAG*, using Gibson assembly we cloned the cDNA encoding *ATRAID* with a C-terminal Flag tag into a homologous recombination vector targeting the *AAVS1* locus, with a GGGGSGGGGS flexible linker (sequence: GGT GGA GGG GGA AGT GGC GGA GGA GGT TCA) added between the CDS and the Flag tag. We transfected this vector along with pX330 expressing an sgRNA targeting

the *AAVS1* locus. To generate the *ATRAID* low expressing cell line (293T *ATRAID_KO* + *ATRAID_{low expr}*), we used the same procedure, but cloned the cDNA encoding *ATRAID* with a C-terminal V5 tag driven by a PGK promoter. Low expression was verified with multiple *ATRAID* expression primers, described below. Mutagenesis to engineer *ATRAID* patient variants was performed with a QuikChange site-directed mutagenesis kit (Agilent) following the manufacturer's protocol. The viral vector, pLenti PGK hygromycin *ATRAID*-V5, used for mutagenesis was previously described (12) and is based on Addgene clone ID: 19066.

sgRNA manipulations. Genome editing experiments were designed based on an established protocol (58). In brief, the sgRNAs for *ATRAID* were cloned using Golden Gate assembly into pSpCas9-BB-2A-GFP (PX438), a kind gift from Feng Zhang (Addgene #48138). All constructs were verified by PCR and DNA sequencing. For the human *ATRAID* locus, one sgRNA targeting exon 3 and another targeting exon 5 were used to act simultaneously and remove part of exon 3, the entire exon 4 and part of exon 5.

Human *ATRAID*:

exon3 sgRNA_1: GCCTGATGAAAGTTTGGACC

exon3 sgRNA_2: CCCTGGTCCAAACTTTCATC

exon5 sgRNA_1: GTCCTGGAGGAATTAATGCC

exon5 sgRNA_2: GTCCTGGAGGAATTAATGCC

Mouse *Atraid*:

GGATACATCGAAGCTAATGC

For generating *Atraid* knockouts in RAW 264.7 cells, cells were transfected with PX438 carrying the above sgRNA, and clones were generated by single cell sorting. Mutation was confirmed by

PCR and sequencing.

Cell viability assays. Wild-type or mutant cells were seeded at 20,000 cells per well in a 96-well tissue culture plate and treated with indicated concentrations of compound or left untreated. 48 or 72 hours after treatment the cell viability was measured using a Cell-titer Glo colorimetric assay (Promega) according to manufacturer's protocol. Viability is plotted as percentage viability compared to untreated control.

For assays of apoptosis, cells were plated in 6-well dishes and exposed to alendronate for 48 hours. AnnexinV positive cells were quantified using flow cytometry with the Dead Cell Apoptosis Kit with AnnexinV Alexa Fluor (488) and PI (Thermo Fisher Scientific #V13241) following the manufacturer's instructions.

Protein analysis. All cells unless otherwise stated were rinsed twice with ice-cold PBS and lysed with Triton-X 100 or NP-40 containing lysis buffer [40 mM HEPES (pH 7.4), 2 mM EDTA, 150 mM NaCl, 50 mM NaF, 1% Triton-X 100 or 1% NP-40, and one tablet of EDTA-free protease inhibitors (Roche) per 25 ml or Halt protease-phosphatase inhibitor (#78442 ThermoFisher Scientific)]. Lysate is incubated at 4 centigrade for 15-30min with constant inversion. The soluble fractions of cell lysates were isolated by centrifugation at 13,000 rpm for 10 min in a microcentrifuge. Lysate protein concentrations were normalized by Bradford assay (Bio-Rad). Proteins were then denatured by the addition of sample buffer and by boiling for 5 minutes, resolved using 4%-20% or 6% (for HDJ-2) SDS-PAGE (Invitrogen), and analyzed by immunoblotting for the indicated proteins. Immunoblotting was performed as follows: nitrocellulose membranes were blocked at room temperature (RT) with 5% non-fat milk for 45min. Membranes were then incubated overnight at 4°C with desired primary antibodies dissolved in 5% milk. Membranes were then washed 3 times in TBST, each wash lasting 5min.

Membranes were then incubated at RT with desired secondary antibodies at 1:2000 in 5% milk for 45 minutes. HRP-conjugated or fluorescent secondary antibodies (Santa Cruz Biotechnology or Thermo Fisher, respectively) were used for detection. Membranes were then washed 3 times in TBST, each wash lasting 5min. Signal from membranes using HRP-conjugated secondary antibodies were captured using a camera and those using fluorescent secondary antibodies were imaged on a GE Typhoon Trio imager. The small GTPase Rap1A protein prenylation can be detected by immunoblot analysis using an antibody that specifically binds to its unprenylated form (59, 60) (Santa Cruz, SC-1482).

RAW 264.7 differentiation. RAW 264.7 cells were maintained in DMEM + 10% FBS + 1X penicillin/streptomycin. Differentiation of RAW cells to osteoclasts was achieved following the protocol of Collin-Osdoby *et al.* (35) where cells were treated with 35ng/ml RANKL (R&D Systems) for 6 days. For experiments with alendronate, the drug was added at the indicated concentrations 48 hours prior to collection.

Primary bone marrow isolation and osteoclast differentiation. Primary bone marrow was isolated from the femurs, tibiae, and spine of wildtype and *Atraid*^{KO} mice, enriched to macrophages and differentiated to osteoclasts following the protocol of Tevlin *et al.* (34). Where indicated, cells were treated with the indicated concentrations of alendronate 48 hours before collection. Note: alendronate responsiveness can differ between different osteoclast cell contexts (61). In our hands, isolated primary osteoclasts were more sensitive to alendronate than the RAW 264.7 cell line. Therefore, we used higher doses of alendronate with RAW 264.7 cells vs. isolated primary cells (30 μ M and 80 μ M vs. 10 μ M and 30 μ M).

Co-culture of primary osteoblasts and osteoclasts. Murine bone marrow macrophages and bone marrow stromal cells were isolated from the long bones of wild-type and *Atraid*-deficient

mice. Murine bone marrow macrophages were differentiated to osteoclasts using M-CSF and RANKL in α -MEM + 10% FBS. Murine bone marrow stromal cells were differentiated to osteoblasts using β -glycerophosphate and ascorbic acid in α -MEM + 20% FBS. 200,000 osteoblasts and 300,000 osteoclasts were co-cultured in six-well dishes in α -MEM + 10% FBS 10 nM 1,25(OH)₂ vitamin D₃, and 100 nM dexamethasone and treated with the indicated concentrations of alendronate for 96 hours followed by tartrate acid phosphatase assay following the manufacturer's protocol. Images of the 6-well dishes were captured by camera and the total TRAP staining on these images was quantified using ImageJ software using the Analyze->Analyze Particle workflow.

Gene expression analysis. Total RNA was isolated and reverse-transcription was performed from cells or tissues in the indicated conditions. The resulting cDNA was diluted in Dnase-free water (1:20) followed by quantification by real-time PCR. mRNA transcripts were measured using Applied Biosystems 7900HT Sequence Detection System v2.3 software. All Data are expressed as the ratio between the expression of target gene to the housekeeping genes RPLP0 and/or GAPDH. Each treated sample was normalized to controls in the same cell type.

Human Primer sequences (for clarity, denoted with prefix: "h" for human):

hATRAID exon1-F' – GGATGGAGGGGCCCCGAGTTTCTG

hATRAID exon2-R' – CCCAAGATGGTGCCCTTCTGATTC

hATRAID exon6-F' – CCATGGATAACAAGTGTATGCGCC

hATRAID exon 7-R' – TCATGAAGTCTTGGCTTTTCGGC

hRPLP0-F' – CAGATTGGCTACCCAAGTGT

hRPLP0-R' – GGAAGGTGTAATCCGTCTCCAC

hTBP-F' – GAGCCAAGAGTGAAGAACAGTC

hTBP-R' – GCTCCCCACCATATTCTGAATCT

Mouse Primer sequences (for clarity, denoted with prefix: “m” for mouse):

mAtraid exon3-F' – GATCTTCAGAACTGTTCCCTGAAG

mAtraid exon4-R' – GCTGAGTAAACCCACGGAAGGTG

mAtraid exon5-F' – CTTCTTTCAAGGACAAGCAGATTTG

mAtraid exon 7-R' – GAATCCCAAAGAACATAAGCAGTG

mActb-F' – TGTCGAGTCGCGTCCA

mActb-R' – ATGCCGGAGCCGTTGTC

mRplp0-F' – TGCTCGACATCACAGAGCAG

mRplp0-R' – ACGCGCTTGTACCCATTGAT

mTnfrsf11a (RANK)-F' – GCAGCTCAACAAGGATACGG

mTnfrsf11a (RANK)-R' – TAGCTTTCCAAGGAGGGTGC

mAcp5 (TRAP)-F' – AAGAGATCGCCAGAACCGTG

mAcp5 (TRAP)-R' – CGTCCTCAAAGGTCTCCTGG

mCtsk-F' – CCTTCCAATACGTGCAGCAG

mCtsk-R' – CATTTAGCTGCCTTTGCCGT

Generation and genotyping of *Atraid* KO mice. Chimeric mice were obtained by microinjection of the correctly targeted *Atraid* EUCOMM ES clones (HEPD0577_2_D01 and HEPD0577_2_E01) (62, 63) into BALB/C blastocysts and crossed with C57BL/6 mice to obtain offspring with germline transmission. Heterozygous mice for the floxed *Atraid* allele (*Atraid*^{loxP/+}), were crossed to C57BL/6 mice expressing the Cre-recombinase transgene from the full-body CMV promoter (64). Mice analyzed in this study were 100% C57BL/6.

All experiments involving mice were performed with protocols approved by the Harvard and Washington University Animal Studies Committees. We confirm that we have complied with all relevant ethical regulations. All mice were housed under a 12 hour light cycle and fed standard chow diet ad libitum.

PCR genotyping of all WT and *Atraid* deficient mice were performed with primers that detect the following:

- 1) This generates a 140bp product and indicates the presence of the transgene.

Transgene (92 upstream) F' CAGCCATATCACATCTGTAGAG

Transgene (92 upstream) R' GAGTTTGGACAAACCACAACACTAG

- 2) This indicates recombination and is detectable in mice also expressing CRE

Del F' CTGCATTCTAGTTGTGGTTTGTCC

Del R' CAGGAGGTAGTGCAAGCCTTTG

- 3) Wild-type *Atraid* primers spanning *Atraid* exons 3 and 4. This PCR product is not detectable in homozygous null animals.

Exon 3/4 F' CAGAACTGTTCCCTGAAGGATCCTGGTC

Exon 3/4 R' GTACACACTGTTAGCGCTCTGTTTGC

4) These generic CRE primers give a ~100bp product indicates the presence of the CRE transgene.

CRE F' GCG GTC TGG CAG TAA AAA CTA TC

CRE R' GTG AAA CAG CAT TGC TGT CAC TT

Serum ELISA assays. Cardiac puncture blood of mice of the indicated ages was obtained and centrifuged at low speed at 4°C for 15 minutes, and serum was isolated. Gla-Osteocalcin (Mouse Gla-Osteocalcin High Sensitive EIA Kit from Clontech, cat.# MK127) and C-terminus cross-linked telopeptides of type I collagen CTX-I (RatLaps EIA Kit from Immunodiagnostic systems Inc., AC-06F1) were quantified following the manufacturer instructions.

Animal procedures. Age and sex matched mice were randomly assigned to treatment groups within each genotype. For the basal characterization of WT and *ATRAID* deficient mice and for the OVX experiments the mice were litter-matched. For the senile osteoporosis experiments the animals were originally derived from the same litter but were bred as cohorts. All animal experiments were replicated two to four times spanning independent days to ensure reproducibility. No outlier animals were excluded from any downstream analysis.

Ovariectomy or sham operations were performed on 3.5-month-old females as detailed previously (65). Briefly, the ovaries were exposed through an abdominal approach and either resected after clipping the blood vessels or left in place (sham operation). The muscle and skin of the abdomen were sutured. Mice were given an intraperitoneal injection of buprenex immediately after surgery and then every twelve hours for 48 hours post-surgery. Immediately preceding OVX, vehicle (phosphate buffered saline) or 100 µg/kg alendronate (both provided by Sigma) was injected intra-peritoneally every week for 4 weeks. These doses were chosen

based on the anti-resorptive activity of alendronate in different species (66, 67). Mice utilized for the senile model of osteoporosis were given the same regime of alendronate for 4 weeks starting at 18 months old. Power calculations and cohort sizes for the senile model experiments were based on the ovariectomy (OVX) model experiment statistical calculations. We acknowledge larger N's would be preferable for the senile model as it is in most experiments. However, it was not feasible within a reasonable time frame to obtain more litter-, sex-, and genotype-matched animals for these studies, especially to reach the age we used, 18 months old to meet the minimum criteria for the mice to be considered "senile". Also, because the referenced experiment was a 2nd supporting model on the more widely used OVX model we felt confident proceeding with the experiment despite it being relatively modestly powered.

Bone microstructure. A high-resolution desktop micro-tomographic imaging system (μ CT40, Scanco Medical AG) was used to assess cortical and trabecular bone microarchitecture and morphology in the femoral mid-diaphysis and distal metaphysis, respectively. Scans were acquired using a $10 \mu\text{m}^3$ isotropic voxel size, 70 kVP peak x-ray tube potential, 114 mAs x-ray intensity, 200 ms integration time, and were subjected to Gaussian filtration and segmentation. Regions of interest (ROIs) were selected 50 slices above and below the femoral longitudinal midpoint or 100 slices above the growth plate of the distal femur to evaluate the cortical and trabecular compartment, respectively. Image acquisition and analysis adhered to the JBMR guidelines for the use of μ CT for the assessment of bone microarchitecture in rodents (24). To judge the effect sizes in our μ CT experiments, it is notable that both OVX and alendronate influenced μ CT parameters in wild-type mice of a magnitude in our hands (~10-20%) that is highly consistent with what has been previously shown in the strain we used, C57BL/6 (32, 68).

Bone biomechanics. Mechanical testing in a 3-point bending to failure was conducted on femora after μ CT. Briefly, hydrated femora were stabilized over supports 7mm apart and a

loading force was applied in the anteroposterior direction midway between the supports (Instron). Test curves were analyzed to determine ultimate force to failure and stiffness as described previously (25, 69).

Bone histomorphometry. To label mineralizing fronts, mice were injected intraperitoneally with calcein (15 mg/kg i.p., Sigma-Aldrich) and alizarin red (30 mg/kg; Sigma) were intraperitoneally injected 7 and 2 days, respectively, before euthanasia. Bone was fixed in 10% (vol/vol) neutral buffered formalin for 24 hours, processed through a series of graded alcohols, and decalcified. Decalcified vertebrae or femurs were embedded in paraffin and 2-4 hours, processed through a series of graded alcohols, and Tartrate resistant acid phosphatase (TRAP) stain was performed. Undecalcified femora were embedded in methyl methacrylate and the whole bone were cut and stained for TRAP or analyzed for calcein and alizarin red fluorescence. Quantitative histomorphometry was performed using a commercial software (OSTEO II, Bioquant), and standard parameters of bone remodeling were determined as detailed elsewhere (70).

Transcriptional profiling analysis. The multiple myeloma, osteonecrosis of the jaw (ONJ) microarray gene expression was performed as previously described (36) using the Affymetrix U133 Plus 2.0 array platform (Affymetrix) on total RNA isolated from peripheral blood mononuclear cells (GEO accession #: GSE71116). 21 multiple myeloma patients with a history of N-BP use were included in the study. 11 patients (52.4%) reported to have ONJ. The breast cancer bone marrow micrometastases (also known as DTC) microarray gene expression data was generated as previously described (37) and also used the Affymetrix U133 Plus 2.0 array platform. DTC profiling was performed on tumor biopsies of 81 patients (GEO accession #: GSE71258). 54 breast cancer patients treated with zometa (zoledronate) were included in the study. N-BPs directly inhibit tumor growth and angiogenesis (71, 72). 14 patients (25.9%) eventually died and 40 patients (74.1%) survived. Her-2 negative patients were divided into two

categories following randomization to the zoledronate arm: those that who had DTC reoccurrences or lived less than 1000 days and those who lived at least 2500 days.

Quantile normalization was used for all differential expression analysis, and all the normalization procedures were performed using function `normalizeQuantiles` in the R Bioconductor package `limma` (73). Gene expression data was filtered using function `filterfun` in the R Bioconductor package `genefilter` (74). Probes with expression values over 5 in less than 25% of the samples were removed. Comparison between groups were estimated using an empirical Bayes method (75), and variances across all genes were used to estimate the variance of each gene. Raw P -values were calculated from a moderated t-test, and false discovery rate (FDR) adjusted P -values were obtained based on Benjamini and Hochberg's methods for multiple testing. Log_2 fold changes between the experimental conditions were calculated for each gene as well.

Affy probe IDs were transformed into gene symbols based on the R Bioconductor package, `hgu133plus2.db` (76). In Fig. 4A, differentially regulated genes for the $-/+$ ONJ patients were identified by having adjusted P -values smaller than 0.05, while potential differentially-regulated genes for the <1000 vs. >2500 days with breast cancer patients with disseminated tumor cells (DTC) were identified by having raw P -value smaller than 0.05. For the ONJ dataset, 1992 genes were significant. For the DTC dataset, 1854 genes were significant.

Exome sequencing analysis. Exome sequencing data was generated from blood leukocyte DNA for 27 bisphosphonate treated osteoporosis cases with atypical femoral fractures (AFF), 11 bisphosphonate treated osteoporosis cases without atypical femoral fractures, and 8 bisphosphonate multiple myeloma or breast cancer cases with osteonecrosis of the jaw (ONJ). Exome capture was performed using Agilent All-exome capture kits. Sequencing was performed using paired-end Illumina sequencing. Analysis of exome sequencing data was performed in-

house using our previously described methods (77, 78). Briefly, FASTQ formatted sequences were aligned to the hg37 human reference sequence (NCBI GRCh37) using BWA (79). Mapped reads were filtered to remove duplicate reads with the same paired start sites. The Binary sequence Alignment/Map (BAM) formatted alignments were then processed using the Genome Analysis Toolkit (GATK) Haplotype Caller (80, 81) and genotypes jointly called together with all in-house control exome sequenced individuals. Variants were filtered for read-depth (>8x), genotype quality (GQ>20), and GATK-calculated variant quality score recalibration (VQSR). Allele frequencies were annotated using the gnomAD database (82). Variant positions were processed excluding those with call rates < 0.95 or Hardy-Weinberg equilibrium P -values < 10^{-5} . Variants were annotated using Seattleseq:

<http://snp.gs.washington.edu/SeattleSeqAnnotation151/>. Genes with multiple variants with non-Finnish European (NFE) allele frequencies less than 0.05 only in cases were considered. From dbSNP, <https://www.ncbi.nlm.nih.gov/SNP/> : For the *ATRAID* gene, the D5G variant is found on chromosome 2 position: 27212382 – rs1275533. The G32R variant is found on chromosome 2 position: 27212297 – rs11556163.

The ethnic breakdown of the AFF cases is: 25/27 European American (EA), 3/27 Asian American (AA), 0/27 African American. The ethnic breakdown of the controls is 8/11 European American and 3/11 unknown. For *ATRAID*, the D5G variant is present in 2 out of 27 AFF patients. Though this allele wasn't detected in the 11 control samples, it is present in a population of European Americans (EA) that is representative of the study population at a prevalence of 0.0139 and in Asian Americans (AA) at a prevalence of 0.002. Therefore, the D5G allele is $(2/27) / (0.0139 * 25/27 + 0.002 * 3/27) = 5.66X$ enriched in cases compared to a representative population to that of the cases. For the G32R *ATRAID* allele the enrichment is: $(2/27) / (0.0149 * 25/27 + 0.002 * 3/27) = 5.28$. Because we have incomplete information on the ONJ cases, we used the EA frequency for our enrichment calculations: the D5G allele is $(1/8) /$

$(0.0139 * 8/8) = 7.19X$ enriched in cases compared to a representative population. For the G32R allele the enrichment is: $(1/8) / (0.0149 * 8/8) = 6.71X$. A simple binomial test, `binom.test()`, was used to calculate the *P*-value for each *ATRAID* variant in AFF and ONJ cases. For the D5G allele, *P*-value = 0.01262 – `binom.test(3, 35, 0.0139)`. For the G32R, *P*-value = 0.01518 – `binom.test(3, 35, 0.0149)`.

Functional validation of *ATRAID* patient alleles. For testing the effects of reduced *ATRAID* expression, *ATRAID* deficient HEK-293T cells were stably infected with sub-endogenous expression of variant “v3” of wild-type *ATRAID*. These cells were then compared with wild-type HEK-293T and the parent *ATRAID* deficient line in cell viability assays. For the rs1275533 variant, the amino acid change, D5G, corresponds to the v3 *ATRAID* amino acid sequence and the same variant is D60G on the longer, v2 *ATRAID* isoform. For the rs11556163 variant, G32R is only present on v2 *ATRAID*. Both *ATRAID* variants were found together in each AFF or ONJ case identified, which suggested these variants are linked. Thus, to recapitulate the patient genotypes, we therefore introduced both v2 and v3 wild-type or variant forms of *ATRAID* in *ATRAID* deficient cells. This means there were three differences between the wild-type and *ATRAID* D5G/G32R variant cell lines we generated – two variants on v2 *ATRAID* and one variant on v3 *ATRAID*.

SUPPLEMENTARY FIGURES







Fig. S1. *ATRAID* is required for the cellular responses to nitrogen-containing

bisphosphonates. (A) Schematic of the exon structure of the three human *ATRAID* mRNA variants. The coding sequence for each variant is in green. Non-coding portions of each exon are in grey. The translated regions of variant 1 and variant 3 are shorter than variant 2 due to

internal translation initiation sites. The location of the primer sets used to identify each *ATRAID* gene trap (GT) are indicated (in blue for *ATRAID*_GT1; in red for *ATRAID*_GT2). **(B)** mRNA analysis of *ATRAID* and *GGPS1* expression in clones that contain independent gene-trap insertions in their respective loci. Wild-type KBM7 cells were compared with mutant alleles (labeled as GT) and *GGPS1* was used as a loading control. **(C)** The growth inhibitory effects of alendronate on WT and *ATRAID* deficient cells over a wide range of concentrations and cell numbers. Viability was determined by measuring cellular ATP and expressed as a ratio of that compared with untreated cells. All measurements were performed in quadruplicate (biological replicates). **P* < 0.05, student's *t*-test. **(D)** Cell growth rate of untreated WT and *ATRAID*-deficient cells. WT and *ATRAID*-deficient HEK-293T cells were plated at the same cell density (10,000 cells/per well), allowed to grow for 48 hours, and ATP was measured. Viability measurements were performed in quadruplicate (biological replicates). Error bars reflect standard deviation. **(E)** The growth inhibitory effects of alendronate on *ATRAID* overexpressing cells. HEK-293T cells were transfected with either Metap2 (control), or *ATRAID*-cDNA expressing vectors and the indicated doses of alendronate for 72 hours. Viability measurements were performed in quadruplicate (biological replicates). **P* < 0.05, student's *t*-test. **(F)** The growth inhibitory effects of alendronate on membrane-targeted vs non-targeted *ATRAID* expressing cells. Cells deficient in *ATRAID* (*ATRAID*_GT2) were transformed to express exogenous Metap2 (control), tubulin (control), *ATRAID* variant 2 (_v2), or *ATRAID* variant 2 lacking the transmembrane domain (Δ mem_v2). Cells were treated with alendronate at the indicated dose for 72 hours. Cell viability was determined as in C. **P* < 0.05, student's *t*-test. (n=6) (3 biological replicates, 3 technical replicates). **(G)** The effects of alendronate and *ATRAID* deficiency on prenylation in an additional cell type, KBM7. Wild-type control and *ATRAID* deficient KBM7 cells exogenously expressing or not expressing *ATRAID* cDNA were treated with the indicated dose of alendronate for 24 hours then lysed and analyzed by immunoblotting for the indicated proteins. Equal amounts of protein were loaded in each lane.

This experiment was repeated three times (biological replicates) and was consistent all three times.





senile (old age, 18 months) osteoporosis model
trabecular (cancellous) bone structure




Fig. S2. Generation and skeletal characterization of *Atraid*^{KO} mice. **(A)** Schematic of *ATRAID* targeted gene locus and genotyping strategy. *Atraid* exon 3-exon 5 are targeted, flanked by LoxP sites. **(B)** Assessment of deletion of protein-coding genomic DNA at the *Atraid* gene locus. WT, wildtype at the *Atraid* locus; het, heterozygous; KO, homozygous deletion. **(C)** Body weights of *Atraid* KO (-/-) and wild-type, WT (+/+) mice from 3 to 20 weeks of age. N=6-13 for wild-type, N=7-14 for *Atraid*^{KO} mice. **P* < 0.05, student's *t*-test. **(D)** *Atraid* mRNA expression in WT and *Atraid*^{KO} mouse tail fibroblast cells were analyzed by RT-qPCR and normalized to *Rplp0* expression. Error bars indicate standard deviation for n=4 (biological replicates). * indicates *P*<0.05, student's *t*-test. **(E)** The growth inhibitory effects of alendronate of cells from the tails of WT and *Atraid*^{KO} mice. All cells were treated with the indicated concentration of alendronate for 72 hours. Cell viability was determined by measuring cellular ATP and is expressed as a ratio of that compared with untreated cells. All measurements were performed in quadruplicate (biological replicates). **P* < 0.05, student's *t*-test. **(F)** *Atraid* mRNA in tibia of WT and *Atraid*^{KO} mice was analyzed by RT-qPCR and normalized to *Rplp0* mRNA expression. Error bars indicate standard deviation for n=4 (biological replicates). **P* < 0.05, unpaired *t*-test. **(G)** Representative traverse μ CT images at the femoral distal metaphysis from wild-type and *Atraid*^{KO} mice. Femur lengths in millimeters (mm) were based on μ CT measurement. Error measurements are standard deviation for n=5-6 mice. * indicates *P*<0.05, student's *t*-test. **(H, I)** Bone microstructure in *Atraid*^{KO} and WT mice. Femur trabeculae (H) and cortical (I) regions were analyzed by μ CT. Each circle represents an individual animal. Circles offset to the right represent unique animals with similar values to those of another animal (offset for visual clarity). N=8-10 (2-month-old) mice per group. n.s. indicates not significant, student's *t*-test. **(J-L)** Bone strength in *Atraid*^{KO} and WT mice. Stiffness (J), yield load (K), and post-yield displacement (L) were analyzed by three-point bending test. Each circle represents an individual animal. Circles offset to the right represent unique animals with similar values to those of another animal (offset for visual clarity). N=8-10 mice (2-month-old) per group. **P* < 0.05, n.s. indicates not significant,

student's *t*-test. **(M, N)** Markers of osteoclast function in *Atraid*^{KO} and WT mice. **(M)** Serum C-terminal telopeptides of type I collagen (CTX-I) were measured in serum obtained from 3-month-old males using ELISA. Each circle represents an individual animal. Circles offset to the right represent unique animals with similar values to those of another animal (offset for visual clarity). N=6 mice per group. n.s. indicates not significant, student's *t*-test. **(N)** Osteoclast surface to bone surface ratio (Oc.S/BS) was determined by Tartrate Acid Phosphatase (TRAP)-assay reactivity. Each circle represents an individual animal. Circles offset to the right represent unique animals with similar values to those of another animal (offset for visual clarity). N=6 mice per group. n.s. indicates not significant, student's *t*-test. **(O, P)** Markers of osteoblast function in *Atraid*^{KO} and WT mice. **(O)** Gla-Osteocalcin was measured in serum obtained from 3-month-old males using ELISA. Each circle represents an individual animal. Circles offset to the right represent unique animals with similar values to those of another animal (offset for visual clarity). N=7-9 mice per group. **P* < 0.05, student's *t*-test. **(P)** Bone formation rate/bone surface (BFR/BS), determined by double labeling using calcein followed by alizarin red, was analyzed histologically. Each circle represents an individual animal. Circles offset to the right represent unique animals with similar values to those of another animal (offset for visual clarity). N=5-7 mice per group. **P* < 0.05, n.s. indicates not significant, student's *t*-test. **(Q, R)** Bone microstructural responses to alendronate in senile osteoporotic (18 month old) *Atraid*^{KO} and WT mice. Femur trabeculae regions from WT and *Atraid*^{KO} mice were analyzed by μ CT. Each circle represents an individual animal. Circles offset to the right represent unique animals with similar values to those of another animal (offset for visual clarity). N=5-8 mice per group. **P* < 0.05, student's *t*-test, and red line indicates mean.




Fig. S3. *Atraid* is required cell-autonomously for the effects of N-BP on osteoclasts in two models of osteoporosis. (A, B) Osteoclast surface and numbers are in WT and *Atraid*^{KO} ovariectomized or senile mice by alendronate treatment. Osteoclast surface per bone surface (Oc.S/BS) (A) and the number of osteoclasts per bone surface (N.Oc/BS) (B) were determined by Tartrate-Resistant Acid Phosphatase (TRAP)-assay reactivity. Each circle represents an individual animal. Circles offset to the right represent unique animals with similar values to those of another animal (offset for visual clarity). N=5-7 mice per group (OVX); N=4-7 mice per group (senile). * $P < 0.05$, n.s. indicates not significant, student's *t*-test and red line indicates mean. (C, D) Osteoblast function after alendronate treatment in WT and *Atraid*^{KO} ovariectomized or senile mice. Mineral apposition rate (MAR) (C) and bone formation rate (BFR/BS) (D) were determined by double labeling using Calcein followed by Alizarin Red were analyzed histologically. Each circle represents an individual animal. Circles offset to the right represent unique animals with similar values to those of another animal (offset for visual clarity). N=5-7 mice per group (OVX); N=4-7 mice per group (senile). * $P < 0.05$, n.s. indicates not significant, and red line indicates mean. (E) Schematic of the mouse *Atraid* first coding exon, indicating the CRISPR-induced mutations present in the two *Atraid*^{KO} clones used in Fig. 3.

Table S1. Results of haploid genomic screen for genes required for the response to alendronate.

Tab (A) List of abbreviations used in this work. (B) Haploid genomic screen results. Enrichment of gene-trap insertions, listed by gene, and ranked by *P*-value enrichment in the alendronate treated vs. untreated populations of cells. After mapping these sequences to the human genome, we counted the number of inactivating mutations (mutations in the sense orientation or present in exon) per individual Refseq-annotated gene as well as the total number of inactivating insertions for all Refseq-annotated genes. For each gene, the *P*-value (corrected for false discovery rate) was calculated using the one-sided Fisher exact test (table S1).

Data file S1. Statistics for *Atraid*^{KO} mice basal characterization, and statistics for bone structure, strength of ovariectomized wildtype and *Atraid*^{KO} animals treated with alendronate.

Tab (A) Data related to Figure 2. Top rows list mean and standard deviation of: cortical thickness, cortical area, trabecular thickness, bone volume/total volume, stiffness, and yield load, from wildtype (WT) and *Atraid*^{KO} (KO) ovariectomized mice treated with vehicle (VEH, saline) or alendronate (ALN). Below rows refer to minimum, 1st quartile, median, 3rd quartile, and maximum of those same measurements. N=6-11 mice (3.5 month old) per group. (B) Data related to Figure S2, basal characterization of wildtype and *Atraid*^{KO} 2-month-old male mice. Top rows list mean and standard deviation of bone volume/total volume, cortical thickness, stiffness, yield load, post-yield displacement, serum total CTX-I, osteoclast surface/bone surface, serum Gla-osteocalcin, and bone formation rate/bone surface in wildtype and *Atraid*^{KO} mice. Below rows refer to minimum, 1st quartile, median, 3rd quartile, and maximum of bone volume/total volume, and bone mineral density. N=8-10 mice per group.

Data file S2. Statistics for bone histomorphometry and serum bone proteins in ovariectomized and senile wildtype and *Atraid*^{KO} animals treated with alendronate.

Tab (A) Bone histomorphometry data, related to Figure 3. Top columns list mean and standard deviation of Serum total CTX-I, osteoclast surface/bone surface from wildtype (WT) and *Atraid*^{KO} (KO) ovariectomized mice treated with vehicle (VEH, saline) or alendronate (ALN). Middle rows refer to minimum, 1st quartile, median, 3rd quartile, and maximum of those same measurements. N=6-11 mice (3.5 month old) per group. N=8-13 mice per group. Bottom rows refer to minimum, 1st quartile, median, 3rd quartile, and maximum counts of # of TRAP positive osteoclasts after of co-culture experiments of wildtype primary osteoblasts with indicated genotype of primary osteoclasts, with indicated alendronate treatment (ALN). (B) Bone histomorphometry data,

related to Figure S3. Top rows list mean and standard deviation of osteoclast surface/bone surface, number of osteoclasts/bone surface, mineral apposition rate, and bone formation rate from wildtype (WT) and *Atraid*^{KO} (KO) 18 month-old senile mice treated with vehicle (VEH, saline) or alendronate (ALN). This is followed by rows detailing the minimum, 1st quartile, median, 3rd quartile, and maximum of those same measurements. Bottom rows refer to number of osteoclasts/bone surface, mineral apposition rate, and bone formation rate from wildtype (WT) and *Atraid*^{KO} (KO) ovariectomized mice treated with vehicle (VEH, saline) or alendronate (ALN). N=5-7 mice per group (OVX); N=4-7 mice per group (senile).

Data file S3. Gene expression, sequencing, and growth phenotype data for ONJ, DTC, AFF and CRISPRi and CRISPRa studies.

All data related to Figure 4. Tab **(A)** Gene expression from bisphosphonate treated patients who did and did not suffer osteonecrosis of the jaw (ONJ) (36). Tab **(B)** Whole exome sequencing bisphosphonate treated cancer patients who experienced ONJ. Tab **(C)**. Gene expression from bisphosphonate treated patients who did and did not suffer bone marrow-disseminated tumor cells (DTC) (37). Tab **(D)** Zoledronate CRISPRi screen results. Mann–Whitney *U* tests determined statistically significant genes. Tab **(E)** Gene-level data on the three genes, ATRAID, ATR, and ZBTB4 that scored across all genome-wide data types – gene expression from patients, CRISPRi screening in human cells, and exome sequencing of patients. Tab **(F)** Atypical femoral fracture (AFF) patient information on the patients that were exome sequenced. Tab **(G)** ONJ patient information on the patients that were exome sequenced.